Artificial ventilated lung exposure system and methods
Patent Information
- Application Number
- PCT/US2025/059774
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-16
- Filing Date
- 2025-12-16
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods fail to accurately simulate and assess human lung inhalation exposures due to the lack of realistic in vitro models that replicate lung anatomy, physiology, and environmental conditions, leading to inadequate representation of exposure risks and toxicity patterns.
An artificial ventilated lung exposure system that integrates an airtight chamber reproducing human lung anatomy, simulates breathing dynamics, and controls environmental factors like temperature and humidity, with integrated access ports for monitoring and cell/tissue exposure.
Enables accurate assessment of intrapulmonary aerosol exposures and pulmonary biologic responses by simulating regional lung conditions, allowing for precise exposure and toxicity analysis.
Smart Images

Figure US2025059774_12112026_PF_FP_ABST
Abstract
Description
Attv. Docket No. 206030-0293-00WGARTIFICIAL VENTILATED LUNG EXPOSURE SYSTEM AND METHODSCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63 / 734,467 filed on December 16, 2024, incorporated herein by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under RO1HL139379 awarded by National Institute of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION
[0003] The human respiratory system is continuously exposed to an array of airborne substances that include indoor and outdoor air pollution, natural disasters and environmental sources, aerosols generated from use of tobacco, cannabis and electronic cigarette (e-cig) products, therapeutic drugs delivered by the aerosol route, natural and manmade bioaerosols, aerosolized construction and occupational exposures, and aerosolized microplastics and nanomaterials [Keswani et al. NEJM Evidence, 1(7): EVIDra2200068, 2022; Wang et al.Science, 373(6558): eabd9149, 2021; Dinakar et al. New England Journal of Medicine, 375(14): 1372-1381, 2016; Sridharan et al. Journal of Hazardous Materials, 418: 126245, 2021; Patel et al. Environmental Chemistry Letters, 19(6): 4253-4274, 2021], Toxic inhalation exposuresAttv. Docket No. 206030-0293-00WG contribute in a substantial manner to global morbidity and mortality resulting from associated respiratory, cardiovascular and other systemic diseases, making the evaluation and management of them a high priority [Li et al. Particle and Fibre Toxicology, 19(1): 67, 2022; WHO. Global Health Estimates, 2024], However, evaluating intrapulmonary inhalation exposures in humans is difficult. Genetic, developmental, behavioral, environmental and exposure differences between individuals are large and complicate the detection of responses to inhalation exposures that can take from days to years to fully manifest. While there has been a heavy dependence on animal exposure studies in the past, critical differences between animal and human respiratory systems, exposure conditions, exposure times and life cycles are problematic. Small animal / rodent lungs also exhibit regenerative properties that make them fundamentally different than human lungs [Massaro et al. Proceedings of the American Thoracic Society, 3(8): 709-712, 2006], As such, when combined with concerns about the ethical use of animals in toxicology research, alternative approaches are needed. The lack of realistic in vitro models for assessing inhalation exposure and toxicity represents a significant challenge to the fields of aerosol research, pulmonary medicine, epidemiology, inhalational toxicology and regulatory science.
[0004] Knowing the characteristics and deposition of inhaled particles as they might occur within human lungs is key to understanding exposure dose and related biological effects [EPA. Guidelines for Exposure Assessment, 1992], However, available research has typically focused on characterizing “emission profiles” or “air sampling”, where-in studies of natural or artificially-generated aerosols are carried out under room temperature and humidity and often through the collection of an arbitrary sample in large collection chambers under static conditions [Das et al. Inhalation Toxicology, 34(3-4): 90-98, 2022; Lee et al. Aerosol Science and Technology, 57(7): 633-644, 2023; Lampos et al. Toxics, 7(3): 45, 2019; Borgini et al.Attv. Docket No. 206030-0293-00WGPulmonology, 2021], Computation modeling, based on these measured characteristics, is then used to estimate intrapulmonary exposure doses, deposition fraction and other features [ICRP. Ann ICRP, 24(1-3): 1-482, 1994; Yue et al. Environmental Science & Technology, 52(12): 6816-6824, 2018; Hammer et al. Aerosol and Air Quality Research, 20(5): 1083-1093, 2020; Madureira et al. Science of The Total Environment, 717: 137293, 2020], Such approaches fail to reproduce or directly measure exposures as they occur in a human lung and therefore fail to adequately represent exposures, risks and patterns of toxicity.
[0005] Thus, there exists the need in the art for an artificial ventilated lung exposure system specifically focused on simulating and integrating key features of the respiratory system including modeled aspects of lung anatomy (including but not limited to lung shape, size, respiratory volumes, airways and alveolar airway structures), physiology (including but not limited to the dynamic processes of inhaling, exhaling, replicating lung compliance and ongoing breathing), appropriate intrapulmonary environmental features (including but not limited to temperature, humidity, intrapulmonary gas composition and pressure changes), and integrated patterns of behavior and exposure (aerosol characteristics and exposure settings, durations, intervals and patterns). Equally important is the need for associated methods to employ this artificial lung system to: 1) detect, analyze and quantify intrapulmonary aerosol exposures as they may exist in key regional locations (e.g. central airways, small airways and alveolar / gas exchange regions) within the lung and 2) repeatedly expose different types of human airway epithelium and pulmonary cell types, which are also region-specific, to the appropriate regional intrapulmonary aerosol exposures. Through this combination of modeling and methods the intended goal would be to obtain accurate assessments of exposure levels and correspondingAttv. Docket No. 206030-0293-00WG pulmonary biologic responses that result from an exposure, at functionally different regions within the lung.
[0006] The present invention uniquely meets these stated needs.SUMMARY OF THE INVENTION
[0007] Some embodiments of the invention disclosed herein are set forth below, and any combination of these embodiments (or portions thereof) may be made to define another embodiment.
[0008] Described is an artificial ventilated lung exposure system designed to both simulate and assess modeled human lung inhalation exposures by integrating a minimum of three (3) key functional components that include:1. An airtight lung exposure chamber that reproduces human lung anatomy in terms of lung shape, specified lung volumes, and the presence of modeled airway structures through which air flows in and out of the exposure chamber.2. A simulation of the dynamic processes involved in breathing that includes, but is not limited to, a) an inhalation phase that delivers a set volume to the lung exposure chamber; b) an exhalation phase that eliminates a set volume from the lung exposure chamber; and c) a control mechanism for adjusting the delivered volumes, respiratory rates and patterns.3. Mechanisms for environmental control that include, but are not limited to, control of temperature, relative humidity, intra-chamber gas composition and volume-associated pressure changes (compliance) within the lung exposure chamber.Attv. Docket No. 206030-0293-00WG
[0009] In some examples, the artificial ventilated lung exposure system includes a series of integrated access ports that can be used for monitoring internal chamber conditions that may include, but are not limited to, temperature, relative humidity, pressure, gas composition, concentration of total or specific volatile organic compounds, particle number concentrations, particle size distributions, particle mass distributions, and particle composition.
[0010] In some examples, the artificial ventilated lung exposure system also includes the capacity to support, in a sterile environment, the culture and exposure of cells and tissues to the environment within the lung exposure chamber during the inhalation of a test sample and during ongoing breathing.
[0011] In some examples, cells and tissues may be placed into the lung exposure chamber for exposure testing.
[0012] In some examples, cells and tissues may be cultured directly on the internal surface of modeled airway structures and lung surfaces for exposure testing.
[0013] In some examples, the lung exposure chamber exhibits a modified conical shape that represents the anatomical proportions of a single human lung, either left or right, or a pair of individual lungs including both a right and a left lung.
[0014] In some examples, the right and left lung compartments may be openly connected within the chamber or divided, in part or in whole, into two or more individual compartments corresponding to anatomical subdivisions of the whole lung.
[0015] In some examples, the specified lung volumes represent any of the following standard subdivisions of lung volume, alone or in combination, including the total lung capacity, inspiratory capacity, functional residual capacity, vital capacity, expiratory reserve volume,Attv. Docket No. 206030-0293-00WG residual volume, inspiratory reserve volume, and tidal volume or a specified fraction (percentage) of stated volumes.
[0016] In some examples, a model of the airway structures through which air flows includes a physical 3-dimensional (3D) representation of the upper airways, in whole or in part, defined as including models for the nasal passages and nasopharynx, mouth and oropharynx and laryngeal airway.
[0017] In some examples, a model of the airway structures through which air flows includes a physical 3D representation of the lower conducting airways, in whole or in part, defined as including models for branching airway structures from the trachea (branch generation 0; GO) to the terminal bronchiole (branch generation 16; G16).
[0018] In some examples, a model of the airway structures through which air flows includes a physical 3D representation of the gas-exchange regions of the lung, in whole or in part, defined as including models representing the cross-sectional areas and / or surface area of the respiratory bronchioles (branch generations 17-19; G17-G19), alveolar ducts (branch generations 20-22; G20-G22), and alveolar sacs (branch generation 23; G23).
[0019] In some examples, the model of the airway structures includes any individual element or a combination of elements selected from the nasal passages and nasopharynx, mouth and oropharynx, laryngeal airway, branching airway structures from the trachea (branch generation 0; GO) to the terminal bronchiole (branch generation 16; G16), and / or the gas-exchange regions of the lung, in whole or in part, defined as including models representing the cross-sectional areas and / or surface area of the respiratory bronchioles (branch generations 17-19; G17-G19), alveolar ducts (branch generations 20-22; G20-G22), and alveolar sacs (branch generation 23; G23).Attv. Docket No. 206030-0293-00WG
[0020] In some examples, the specific elements included in the model of the airway structures are set to match the flow characteristics appropriate for the type of airway cells and airway epithelium that are present in the corresponding region of the lung; thereby producing a region-specific exposure condition such as the central airway airflow matched to human bronchial cells and human bronchial epithelium, the conducting airway region matched to small airway cells and small airway epithelium, and the gas-exchange regions of the lung matched to alveolar cells and alveolar epithelium.
[0021] In some examples, the relative size and 3D-structure of the modeled airway parts are derived from methods including, but not limited to, anatomic measurements, castings prepared from human lungs, data generated from computerized tomography imaging of the airways, theoretical modeling and in silica simulations.
[0022] In some examples, the described features of the lung exposure chamber can be generated through processes including, but not limited to, molding, extrusion, 3D-printing, fabrication, mechanical assembly, welding, and fusion.
[0023] In some examples, the mechanism to simulate the inhalation and exhalation of a breath may include, but are not limited to, the attachment of a ventilator, lung volume simulator, respiratory bellows, two-way syringe system, aerosol generating device, or a pressurized gas flow device.
[0024] In some examples, the breath may be delivered using a positive pressure to force a breath into the lung exposure chamber.
[0025] In some examples, the breath may be delivered through the generation of a negative pressure within the lung exposure chamber that draws in the breath from an external air source.
[0026] In some examples, the delivery of the inspiratory breath includes a mechanism forAttv. Docket No. 206030-0293-00WG introducing a test aerosol into the inhaled breath.
[0027] In some examples, the mechanisms to simulate the exhalation of a breath occur through an active process such that when triggered it will actively remove a breath.
[0028] In some examples, the mechanisms to simulate the exhalation of a breath occur through a passive process mediated by the elastic rebound properties, also termed compliance, of the artificial ventilated exposure chamber system.
[0029] In some examples, the elastic rebound properties of the artificial ventilated exposure chamber may be determined by one or more of the following, but is not limited to, the use of attached lung test balloons, respiratory bellows, a two-way syringe system, a lung simulator device, elastic material used in production of the airway structures, and elastic materials used in production of the exposure chamber walls.
[0030] In some examples, the adjustable controls for the respiratory rate and tidal volume may be provided as a component of the device(s) that provides the inhalation and exhalation
[0031] In some examples, the adjustable controls for the respiratory rate and tidal volume are provided or as part of a central control software that integrates different operational components into a central computer-controlled process.
[0032] In some examples, the temperature within the lung exposure chamber is independently controlled, with respect to the existing room environment, through use of at least two different heat sources.
[0033] In some examples, one heat source is a heated ventilator circuit that heats the air, gas and aerosol sources as they travel through tubing that delivers them into the lung exposure chamber with each breath.
[0034] In some examples, one heat source independently heats the lung exposure chamberAttv. Docket No. 206030-0293-00WG from the outside to assure uniform temperature control throughout the model and to specifically prevent condensation on either the interior or exterior surfaces of the chamber and modeled airway structures.
[0035] In some examples, humidity is controlled, in whole or in part, through use of a heated ventilator humidifier circuit.
[0036] In some examples, humidity is controlled, in whole or in part, through use of a heated water reservoir contained within the lung exposure chamber.
[0037] In some examples, the chamber gas composition within the lung exposure chamber is controlled by delivering air and gases into the chamber from sources that may include, but are not limited to, room air, a sample chamber that contains a controlled gas composition, and the use of different compressed gas sources in combination with pressure and gas-mixture regulating valves as needed to obtain the desired gas composition.
[0038] In some examples, the preferred gas composition is 21% Oxygen, 5% Carbon Dioxide and remainder Nitrogen.
[0039] In some examples, a central integrated software program integrates and controls the various adjustable features of the artificial ventilated lung exposure system.
[0040] In some examples, the system includes a temperature-controlled incubator including at least one port, an artificial lung chamber positioned within the incubator in fluid connection with the at least one port and comprising a plurality of walls, an airway model at least partially positioned within the artificial lung chamber, at least one test lung balloon in fluid connection with the artificial lung chamber, and at least one sensor within the artificial lung chamber. In some examples, the at least one port comprises an inspiratory port, an expiratory port, and one or more aerosol sampling ports. In some examples, the at least one port comprises a valve to controlAttv. Docket No. 206030-0293-00WG the flow of inhalation and exhalation. In some examples, the system further includes an agitator positioned within the artificial lung chamber. In some examples, the at least one sensor comprises any of a pressure sensor, a temperature sensor, a humidity sensor, a biosensor, or a gas sensor. In some examples, the artificial lung chamber is sized and shaped to mimic a human lung. In some examples, the artificial lung chamber has a capacity of 5 to 7 liters. In some examples, the airway model is manufactured from any of, a flexible material, a transparent material, a resin material, a semi-porous material, a non-porous material, a porous material, a 3D printed material. In some examples, the airway model comprises an upper airway portion connected to a lung portion. In some examples, the airway model comprises a reinforcing sidewall configured to provide a non-collapsible structure to the flexible transparent material of the upper airway portion. In some examples, the airway model comprises one or more cells, organoids, cell cultures, tissue scaffolds, tissue cultures, hydrogels, each embedded within the airway model, or layered on a surface of the airway model. In some examples, the one or more cells are selected from lung cells, stem cells, epithelial cells, endothelial cells, alveolar cells, macrophages, muscle cells, fibroblasts, nerve cells, growth factors, human umbilical vein endothelial cells (HUVEC), or mesenchymal cells. In some examples, at least one of the incubator, artificial lung chamber, and airway model are transparent. In some examples, the system further includes a gas source in fluid connection with the incubator via a ventilator and a humidifier. In some examples, the gas source comprises 5% CO2, 21% O2, and 74% N2.
[0041] Also described is an inhalation exposure assessment method. The method includes providing any of the systems disclosed herein, capturing one or more images of a subject’s upper airway, producing a digital reconstruction of at least a portion of the subject’s respiratory system with the one or more images, producing an airway model based on the digital reconstruction, andAttv. Docket No. 206030-0293-00WD positioning the airway model at least partially within the artificial lung chamber. Tn some examples, the method further includes the step of sampling one or more cells from the subject, and culturing the one or more cells on the airway model. In some examples, the method further includes the step of treating the airway model with one or more treatments. In some examples, the treatment is selected from: chemotherapy therapy, radiation therapy, immunotherapy, vaccine therapy, stem cell therapy, aerosolized treatments, or nebulized treatments. In some examples, the method further includes the step of measuring one or more analytes from the artificial lung chamber using the at least one sensor.BRIEF DESCRIPTION OF THE DRAWINGS
[0042] The foregoing purposes and features, as well as other purposes and features, will become apparent with reference to the description and accompanying figures below, which are included to provide an understanding of the invention and constitute a part of the specification, in which like numerals represent like elements, and in which:
[0043] FIG. 1 depicts an exemplary embodiment of the three key functional components of an artificial ventilated lung exposure system according to one aspect of the present invention.
[0044] FIG. 2 depicts an exemplary flow path for a simulated breathing cycle using the disclosed artificial lung system according to one aspect of the present invention.
[0045] FIG. 3 is a diagram of an exemplary embodiment of an artificial ventilated lung exposure system equipped with several particle monitoring probes, instruments and chamber sampling ports, and configured to produce a flow path that integrates simulated vaping in combination with ongoing breathing.Attv. Docket No. 206030-0293-00WG
[0046] FIG. 4 depicts an illustrative computer architecture for a computer for practicing the various embodiments of the invention.
[0047] FIG. 5 is a plot showing real-time intrapulmonary monitoring results for air pressure changes (relative to atmospheric pressure) within the lung chamber vs time for a simulated pattern of coordinated breathing and vaping.
[0048] FIG. 6 is an image of the lung exposure chamber demonstrating the capacity to insert standard sterile culture plates within the chamber environment in order to study the effects of regional inhalation exposures on human airway epithelial cells, whole lung epithelium or any type of cell culture under air liquid interface conditions.
[0049] FIG. 7 is a pair of images demonstrating the differences in inhaled air flow characteristics as they occur at the level of the trachea as compared to how they occur after passing through the conducting airway model through airway generation 13 (G13).
[0050] FIGs. 8A & 8B are representative plots of modeled airway flow velocities at different levels throughout the 3D printed airways (FIG. 8A) and of average kinetic energy calculations for each airway generation for a single continuous path through each lung, right and left (FIG. 8B).
[0051] FIG. 9 is a plot showing real-time monitoring results for dilution-corrected particle number concentrations (PNCs) within the lung chamber vs elapsed time when a simulated 4-puff vaping session is integrated with a normal breathing pattern.Attv. Docket No. 206030-0293-00WG
[0052] FIG. 10 is a plot showing real-time results for dilution-corrected PNC vs elapsed time when a simulated 4-puff vaping session is carried out in the presence or absence of ongoing breathing at 10 breaths per minute with a breath size of 480 ml.
[0053] FIGs. 11 A & 1 IB are plots showing real-time results for dilution-corrected PNC vs elapsed time (FIG. 11 A) and area under the curve exposure levels within the ventilated lung model (FIG. 1 IB) when a simulated 4-puff vaping session is carried out in the presence of different breathing patterns.
[0054] FIG. 12 is a plot showing results for measured mean peak PNC levels and area under the curve (AUC) exposure levels plotted as a function of different minute ventilation levels, with associated linear regression equations and correlation coefficients (r2).
[0055] FIG. 13 is a plot comparing calculated mean particle decay rates vs the total minute ventilation (MV) within the chamber as a consequence of the different breathing patterns, with the associated linear regression equation and correlation coefficient (r2).
[0056] FIG. 14 is a plot showing results for the differential number concentration of particles as a function of the logarithm of their diameter (dN / dlogDp) vs aerodynamic diameter that was measured within the lung chamber when it was operated under either standard room or lung environment conditions.
[0057] FIG. 15 is a plot showing results for the differential mass concentrations of particles as a function of the logarithm of their diameter (dM / dlogDp) vs aerodynamic diameter that was measured within the lung chamber when it was operated under either standard room or lung environment conditions.Attv. Docket No. 206030-0293-00WG
[0058] FIG. 16 shows representative snapshot images of the aerosol clouds forming in the lung chamber at the end of a 4-puff vaping session (the time of peak exposure) under different environmental conditions that reflect either a “room environment” or a “lung environment”, under the condition where the vaping exposure has occurred in the presence of continuous ongoing ventilation.
[0059] FIG. 17 is a chart summarizing the two primary modes for the aerodynamic diameter distributions for inhaled e-cig aerosol particles that were measured under either the room or lung environment conditions, along with the total number concentration and mass concentrations resulting from these different exposure conditions.
[0060] FIG. 18 is a chart showing how the lung environmental conditions, as compared to the room environmental conditions, alters the distribution of particle mass concentrations (PMCs) that result within the lung exposure chamber following the inhalation of e-cig aerosol.
[0061] FIG. 19 is a plot showing the predicted changes in the lung deposition fraction of inhaled e-cig aerosol particles, by lung region, depending on whether the aerodynamic diameters were measured under room environmental conditions or lung environmental conditions.
[0062] FIG. 20 is a plot showing the predicted changes in the lung deposition dose (mass) for inhaled e-cig aerosol particles, by lung region, depending on whether the aerodynamic diameters were measured under room environmental conditions or lung environmental conditions.
[0063] FIG. 21 is a plot showing results for the measured airway deposition fraction, when particles of different sizes (aerodynamic diameters) are aerosolized and inhaled into the lung chamber through a combination of upper mouth airways with the conducting airways modeledAttv. Docket No. 206030-0293-00WG through generation 13, and compares it to the predicted findings from the Multiple-Path Particle Dosimetry Model.
[0064] FIGs. 22A, 22B & 22C are a set of exemplary embodiments of an artificial ventilated lung exposure system in which the lower airways are configured differently in each embodiment to reproduce a unique regional intrapulmonary exposure condition (central airway (FIG. 22A) vs bronchiolar (FIG. 22B) vs alveolar (FIG. 22C)) that can be paired with an appropriate human lung epithelial cell culture as a means for investigating both regional lung exposures and associated region-specific inhalation toxicity.
[0065] FIGs. 23A-23E describe an example of an exposure assessment (FIGs. 23 A, 23B, 23C & 23E) and a toxicity outcome assessment (FIGs. 23D & 23F) that can be performed using the artificial ventilated lung exposure system to assess the effects of repeatedly vaping whole Juul pod aerosol, or individual constituents of the Juul pod e-liquid, onto human bronchial epithelial cell cultures maintained within the exposure chamber over a period of 2 days and exposed to 13 vaping sessions each day, each session with 4 puffs.DETAILED DESCRIPTION OF THE INVENTION
[0066] It is to be understood that the figures and descriptions of the present invention have been simplified to illustrate elements that are relevant for a clearer comprehension of the present invention, while eliminating, for the purpose of clarity, many other elements found in systems and methods of artificial lung exposure systems. Those of ordinary skill in the art may recognize that other elements and / or steps are desirable and / or required in implementing the present invention. However, because such elements and steps are well known in the art, and becauseAttv. Docket No. 206030-0293-00WG they do not facilitate a better understanding of the present invention, a discussion of such elements and steps is not provided herein. The disclosure herein is directed to all such variations and modifications to such elements and methods known to those skilled in the art.
[0067] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are described.
[0068] As used herein, each of the following terms has the meaning associated with it in this section.
[0069] The articles “a” and “an” are used herein to refer to one or to more than one (z.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0070] “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, and ±0.1% from the specified value, as such variations are appropriate.
[0071] Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Where appropriate, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to haveAttv. Docket No. 206030-0293-00WG specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
[0072] Referring now in detail to the drawings, in which like reference numerals indicate like parts or elements throughout the several views, in various embodiments, presented herein is an artificial lung exposure system and method.
[0073] Disclosed herein is a novel artificial ventilated lung exposure system designed to both simulate and assess modeled human lung inhalation exposures in an anatomically and physiologically relevant manner by integrating a minimum of three (3) key functional components that are integral to all embodiments.
[0074] The first key component is an airtight lung exposure chamber that reproduces lung anatomy in terms of the conical shape and volume of the overall lung and the presence of 3D modeled airway structures through which ventilated air travels. The airtight nature of the lung exposure chamber creates a closed-circuit system that is essential for delivering a reproducible and uniform pressure gradient that directs airflow through the included airway structures and into / out of the lung chamber [Mellema. Top Companion Anim Med, 28(3): 112-123, 2013], As in real life, the development of a leak in the airway or lung structures (a rupture or fistula) results in a disruption of the normal airflow patterns, loss of gas or aerosols that were to be delivered to the lung, and an overall loss of ventilatory capacity and aerosol clearance from the lung.Therefore, the construction of the lung exposure chamber must use methods and approaches to assure its airtight qualities and an ability to withstand pressure changes associated with ventilation (typical range -20 cmkhO to +20 cmthO; extreme range -40 to +40 cmthO). InAttv. Docket No. 206030-0293-00WG various embodiments, the lung exposure chamber may be generated through a variety of manufacturing processes that can achieve the defined specifications including, but not limited to, molding, extrusion, 3D-printing, fabrication, assembly, welding, and fusion.
[0075] In one embodiment, the conical shape refers to the vertical (upright) orientation of a pair of human lungs, and its various lobes and subdivisions, which create a 3D structure that is larger in dimensions at its base then at its apex, and larger across its width than its depth, with a well described range of anatomical proportions for its individual lungs (right and left) and their lobes [Standring. Gray’s Anatomy, Elsevier, 2020], In other embodiments, the lung exposure chamber may be configured to represent the conical shape of a single lung; right or left. The vertical / upright orientation of the human lung is distinct from that present in rodents and other four-legged animals and is therefore associated with a distinctly different pattern of ventilation and airflow that is approximated by the current invention and incorporated into its design. In other embodiments of the invention, in which the conical lung shape is maintained, the orientation of the lung chamber itself may be varied to reflect exposures occurring in reclining, lateral, sleeping or other positions.
[0076] For the current invention, creating representative human lung volumes is essential for producing realistic estimates of the concentration, distribution and properties of inhaled gas and aerosols as they might occur in a native human lung [Hall et al. European Respiratory Journal, 57(3): 2000289, 2021], Realistic human lung volumes are also essential for assessing the dynamic changes in aerosol characteristics that occur in response to ongoing ventilation. For example, in the case of an aerosol exposure such as that occurring from a cigarette-like device or a medicinal aerosol generator, there is a certain aerosol puff volume that must be diluted within a specific breath volume and then diluted further within the larger lung volume that occupies theAttv. Docket No. 206030-0293-00WG gas exchange regions of the lung [Sosnowski et al. Frontiers in Physiology, 9: 853, 2018], For the practice of this invention, specified lung volumes are chosen from the following standard subdivisions of lung volume, alone or in combination, including the total lung capacity, inspiratory capacity, functional residual capacity, vital capacity, expiratory reserve volume, residual volume, inspiratory reserve volume, and tidal volume or a specified fraction (percentage) of stated volumes. The lung volumes to be employed in any specific embodiment of this invention should be determined by the intended use. In one embodiment, for example, which focuses on intrapulmonaiy exposure conditions during the normal ranges of breathing, the selected volume of the lung exposure chamber can be set at functional residual capacity (the volume remaining in the lungs after a normal, passive exhalation, but before inhaling the next breath) plus a selected percentage of the inspiratory capacity (the maximal breath that one can take into the lungs after you breathe out normally). In another embodiment, focusing on replicating a conditioned athletes during maximal exercise, the chamber volume could be set at total lung capacity. In another embodiment that employs an elastic or flexible lung exposure chamber designed to mimic the expansion or compression characteristics of the human lung under different breathing conditions, the resting exposure chamber might be set at functional residual capacity so that it automatically expands or contracts to accommodate a delivered breath no matter the volume The ability to make adaptations to accommodate different human conditions is one of the inherent features of the described invention. Lung volumes vary between people, but on average can be characterized for the purpose of creating specific embodiments of this invention by employing standard pulmonary function calculators or equations that provide average estimates for each subdivision of lung volume based on a selected age, height, gender and other anthropomorphic features as should be well known to those practicing in this field andAttv. Docket No. 206030-0293-00WG exemplified in the noted reference [Hall et al. European Respiratory Journal, 57(3): 2000289, 2021], For example, the predicted average lung volumes for an adolescent child 12 years old and 4 ft tall, an adult woman 5.5 ft tall and an adult male 6 ft tall are significantly different and the size of the employed lung exposure chamber used to investigate inhalation exposures for such examples may need to vary depending on the proposed needs of the predicted outcome data. Given this background and the described specifications, it should be clear to an individual skilled in the art that measuring aerosol characteristics in a system that does not replicate realistic estimates of human lung volumes, as specified in this invention, will obviously fail to accurately model intrapulmonary exposure. Further, the relative concentration of an inhaled aerosol may directly impact on aerosol dynamics that include, but are not limited to evaporation, condensation, coagulation, and phase-transitioning [Hinds et al. John Wiley & Sons, 2022], As a result, reproducing the airtight nature, shape and lung volumes associated with a human lung are all essential components of this invention and required to create a lung exposure system that focuses on simulating and assessing lung exposure conditions.
[0077] An equally important component of the lung exposure chamber is the inclusion of 3D-modeled airway structures. The lung is not simply an empty chamber into which a breath of air flows and mixes. It contains an intricate pattern of branching airway structures that create defined regions within the lung. Each region has a different set of anatomic, physiologic, and biologic functions, is associated with a different pattern of airflow, exhibits different particle deposition characteristics and gas-exchange features, and is lined by a different type of airway epithelium and associated airway cells [Baker. Artificial Ventilation: A Basic Clinical Guide, pp. 27-42, 2020; Luks. West’s Respiratory Physiology, pp. 1-14, 2020], For example, to deliver adequate minute ventilation to support gas exchange requirements, airflow rates at the level ofAttv. Docket No. 206030-0293-00WG the upper airways are characteristically high (ranging 8-60 liters / min) and turbulent in nature, which favor the deposition of micron-sized (or larger) particles onto the upper and central airway mucosal surfaces. The upper airway, including the nasal passages and nasopharynx, mouth and oropharynx and laryngeal airway act to fdter, channel, and sample incoming air and to heat and humidify it [Pohunek. Paediatric Respiratory Reviews, 5(1): 2-8, 2004], The branching airway structures associated with the conducting regions of the lung produce an exponential expansion of luminal cross-sectional area that serves to simultaneously slow airflow, transition airflow patterns from turbulent to laminar profdes, and promote relatively homogenous and simultaneous distribution of the inhaled breath to all lung regions [Davies et al. The Respiratory System (Second Edition), pp. 11-28, 2010], In the gas exchange regions of the lung, the expanding cross- sectional nature of the airways further slows airflow rates to near-diffusion levels and delivers inhaled samples to the expansive alveolar surface area involved in gas exchange and particles deposition [Miller et al. Journal of Aerosol Science, 99: 14-26, 2016], In different embodiments of the proposed invention, the relative size and 3D-structure of the modeled airway parts may be derived from methods including, but not limited to, anatomic measurements, castings prepared from human lungs, data generated from computerized imaging of the airways, theoretical modeling and in silico simulations. In a similar manner, the described features of the 3D airway models can be generated through processes including, but not limited to, molding, extrusion, 3D- printing, fabrication, mechanical assembly, welding, and fusion. As such, a unique and essential component of this invention is the development of a lung exposure chamber that recreates the regional characteristics of the airways and the capacity to adapt the airway models to study different, and region-specific, lung exposures. For example, inhaled bronchodilator medication may require aerosol targeting to the conducting airways in order to regulate bronchial muscleAttv. Docket No. 206030-0293-00WD tone [Sosnowski. Pharmaceutics, 16(1), 2024], Similarly, components of inhaled tobacco products that land on the central and small conducting airways may mediate the pathogenesis of chronic bronchitis while inhaled tobacco products that deposit in the alveolar and gas exchange regions of the lung may lead to the generation of emphysema. As such, by adapting the 3D airway model that is included within the chamber, one can differentially simulate and assess region-specific exposure conditions, deposition, and biologic consequences in a unique manner not currently available through other inhalation exposure systems. In other embodiments, the 3D airway structures are fabricated so as to facilitate the attachment, nutritional support and growth of human airway epithelial cells of the type appropriate for each region of the lung in order to directly link exposures to various biologic measures of toxicity. Collectively, through the combination of these features, the lung exposure chamber represents a novel advance in the ability to create and assess modeled lung exposures at specific regional levels within the lung.
[0078] The second key component of this system involves the integration of a ventilatory component - a mechanism to simulate the dynamic processes involved in breathing that includes, but is not limited to, a) an inhalation phase that delivers a set volume to the lung exposure chamber; b) an exhalation phase that eliminates a set volume from the lung exposure chamber; and c) a control mechanism for adjusting the delivered volumes and respiratory rate. Most other models for investigating inhalation exposures and their biologic consequences fail to recreate the dynamic processes involved with breathing / ventilation which can directly impact on regionspecific lung exposure conditions in a temporal manner. In the most basic toxicology assays for inhalation exposure, an arbitrary amount of aerosol is passed through tissue culture media to create “aerosol conditioned media” (ACM), which can then be evaluated to determine the absorbed aerosol components and / or tested for its toxicity by adding ACM to cells growing inAttv. Docket No. 206030-0293-00WG culture [Ma et al. Environment & Health, 1(5): 315-323, 2023], This typically concentrates the aerosol constituents to extremely high levels, often containing hundreds of puffs concentrated into culture media, and then exposes cultures to such doses in a continuous manner for hours to days. While these approaches have merit and might assess the “potential” of the aerosol constituents to produce toxic effects, it is unclear how the exposure or observed outcomes relate to naturally occuring lung exposures. In other approaches for assessing aerosol exposure or toxicity, an aerosol is generated, usually in combination with a set dilution with fresh air, and investigated for its toxicity. In many cases, toxicity assessment is carried out under what is termed “air-liquid-interface” (ALI) conditions in which cultured cells are adapted to live on the surface of a support membrane so that they are exposed to air on their apical surface and culture media on their basal surface [Cao et al. In Vitro Cell Dev Biol Anim, 57(2): 104-132, 2021], ALI cultures can recreate many aspects of the epithelium lining the lung and therefore facilitate studies involving direct aerosol exposure to the surface of cells. However, systems that deliver either continuous or intermittent pulses of an aerosol stream to ALI cultures still fail to recapitulate intrapulmonary exposure conditions. To do so requires the integration of a process that recreates lung shape, relative lung volumes and regional airflow characteristics with a process that delivers ventilation in a manner similar to that occurring during the process of breathing. In the proposed invention, puffs or aerosols from smoking, vaping, medical aerosol devices or other sources (such as environmental air exposures or exposure chambers) can be inhaled in specific coordination with a breath. This results in a process of serial dilution and distribution. The puff is diluted within the volume of an inhaled breath, mixed by the turbulent airflow characteristics associated with upper airway and central airway airflow patterns, and then distributed throughout the lung and mixed with the larger lung volume that occurs at the end ofAttv. Docket No. 206030-0293-00WG an inhalation. Aerosol particles deposit on the surfaces of the airways as they pass through them in a size, mass, airflow and region-specific manner [Davies et al. The Respiratory System (Second Edition), pp. 11-28, 2010], After this initial exposure, the majority of inhaled particles remain suspended in the gas volume of the lung and are serially diluted, deposited and / or removed over time by ongoing ventilation. The volume and rate of ventilation, in combination with the size and anatomy of the lung and airways, control the process of serial dilution and exhalation that results in ongoing breathing being able to eliminate suspended particles from the lung. The current invention recreates this dynamic exposure paradigm by introducing active breathing patterns. The addition of ventilation (breathing patterns) results in a fundamentally different pattern of exposure as compared to the standard practice of exposing target cells to a continuous or intermittent flow of a fixed dilution of aerosol. As such, the exposure conditions associated with the current invention are novel. To be adaptive, the ventilation provided by the proposed device must include a mechanism for controlling at least the tidal volumes and respiratory rate associated with the breathing process, but such controls should extend by common convention to include controls for flow rates, flow patterns, inspiratory times, pauses, breath holds and other controls for the pattern by which ventilation (breathing) is delivered. Within the current model, embodiments exist by which the ventilation can be delivered through the administration of positive pressure (forcing an inhalation into the lung; similar to support provided by a standard clinical ventilator) or through the administration of negative pressure (creating a vacuum effect within the chamber that draws air into the lung; similar to the process of native breathing). In some embodiments of this system, the individual inhalation and exhalation of a breath can be modeled to occur spontaneously, in response to changes in lung compliance and / or elasticity, or when triggered by another event such as timing or the delivery ofAttv. Docket No. 206030-0293-00WG a pre-set volume or pressure. Mechanisms for simulating the elastic rebound properties of the artificial ventilated exposure chamber may include the following, but are not limited to, the use of attached lung test balloons, respiratory bellows, a two-way syringe system, a lung simulator device, elastic material used in production of the airway structures, and elastic materials used in production of the exposure chamber walls. A number of mechanisms are available to deliver controlled breaths and simulate ventilation including, but not limited to, the use of a ventilator, lung volume simulator, respiratory bellows, a two-way syringe system, aerosol generating device, or a pressurized gas flow device. In some embodiments, such devices may provide their own individual control systems or in other embodiments, the control of ventilation may be integrated into an overall central system control panel through the use of associated interconnecting hardware and software. Central to operation of this device for inhalation exposures is the capacity to integrate a mechanism whereby a puff of aerosol is appropriately timed and delivered in conjunction with a delivered breath.
[0079] The third key component of this ventilated artificial lung exposure system is the inclusion of mechanisms for environmental control of features that include, but are not limited to, temperature, relative humidity, intra-chamber gas composition and volume-associated pressure changes (compliance) within the lung exposure chamber. It is typical, in the field of inhalation exposures, for aerosol emissions or air exposure conditions to be studied in large chambers and / or under standard room temperature and atmosphere conditions [Son et al. Chemical Research in Toxicology, 33(2): 343-352, 2020], However, temperature and relative humidity directly interact with aerosols to promote changes in evaporation, coagulation, phasetransitioning and hygroscopic growth [Sosnowski et al. Frontiers in Physiology, 9: 853, 2018], Particle size distributions, number-concentrations and mass can significantly change in responseAttv. Docket No. 206030-0293-00WG to temperature and humidity and therefore impact on the distribution and deposition fraction when an aerosol is inhaled into the lung. The generation of volatile organic compounds (VOC), another important aspect of inhalational toxicity, is also impacted by temperature and humidity [Huang et al. Scientific Reports, 6(1): 23388, 2016; Zhu et al. Building and Environment, 262: 111845, 2024], An important feature of the disclosed system is the capacity to independently adjust these environmental conditions, separate from the room environment, to facilitate the study and validation of lung exposure modeling and provide empiric measurements of the impact of environmental changes on intrapulmonary exposure. As gas and aerosols enter the lung, they are rapidly warmed to body temperature and humidified to levels that range from 88% to 99% relative humidity (RH). In one embodiment of the current invention, two independent heating and temperature control systems are used in combination to control the modeled lung temperature evenly throughout the system and prevent surface condensation. One source for both heating and humidity is to control the temperature of the air, gas mixture and / or aerosol that is introduced into the system with each breath. This can be achieved through several approaches, including but not limited to, the use of a heated and humidified gas source, a heated and humidified chamber from which the inhaled breath is obtained, or through the use of a conventional heated humidifier airway circuit as used in the standard application of mechanical ventilation for patient care. However, heating and humidifying the inhaled gas source alone may not be sufficient to produce a uniform temperature and prevent condensation. As such, in some embodiments the system comprises a second heat source capable of heating from a source external to the surface of the lung exposure chamber. External heating can occur from the use of an environmental control chamber, such as an incubator, into which the lung exposure chamber is placed. External heating might also occur through the use of an external source of heated air,Attv. Docket No. 206030-0293-00WG heating lamps, or electrical resistance wiring integrated with the surface of the chamber. Collectively, according to the design of this system, the combination of an internal and an external heat source provides the optimal control of chamber temperature. In one embodiment, humidification that is provided through the ventilation system, as detailed above, can be supplemented by the addition of a heated water source within the lung exposure chamber to achieve the required humidification conditions.
[0080] Depending on the intended application of the system, it may also be important to control the gas composition of air that is introduced into the artificial ventilated lung exposure system. This is particularly the case when introducing cells for culture and exposure within the artificial lung exposure chamber. The lung environment is unique in acting as the primary gas exchange surface that regulates CO2 levels. In contrast to room air, which contains very limited CO2 content, the gas within the lung closely approximates 5% CO2 [Siobal. Respiratory Care, 61(10): 1397-1416, 2016], Reproducing the lung environment for cell exposure studies is therefore optimally carried out with a gas composition that contains 21% oxygen, 5% CO2 and the remainder nitrogen, a gas composition that provides an optimal condition for human cell culture and closely approximates that within the native lung. However, regulating gas compositions with other mixes may also be applicable during experimental protocols that evaluate hypoxemia, systemic acidosis or other alterations or physiologic variations. In this invention, the gas composition can be regulated at the level of the air that is introduced into the lung with each breath, through the use of pressurized gas cylinders with defined compositions, or through the use of gas mixing valves and regulators that directly control gas composition within the chamber.Attv. Docket No. 206030-0293-00WG
[0081] The final environmental feature defined as an essential component of this system is the capacity to regulate volume-associated pressure changes (compliance) within the lung exposure chamber. Pressure gradients provide the fundamental mechanism by which air moves through the airways and into / out of the lung during ventilation. As noted, air can be drawn into the lung exposure system by a negative pressure gradient, as occurs during spontaneous breathing, or air can be forced into the lung using a positive pressure gradient, as occurs during the process of mechanical ventilation [Grinnan et al. Critical Care, 9(5): 472, 2005], However, introducing volume into a rigid or semi-rigid (and airtight) exposure chamber will create resistance that alters flow patterns, therefore impacting on the dilution and distribution of inhaled aerosols. Applied volume changes in this setting also elevate internal exposure chamber pressures to levels that impact on the biologic function and viability of cells and tissues cultured there-in. The human lung, in vivo, accommodates for volume-associated pressure changes by expanding and contracting the lung volume during the respiratory cycle through the use of its elastic properties, tissues and muscles involved in the process of breathing [Grinnan et al.Critical Care, 9(5): 472, 2005], The normal human lung has an innate compliance in the range of 40-100 ml / cmH20 applied pressure and the invention presented here is designed to replicate this elasticity / compliance through the following means, which include but are not limited to, the use of attached lung test balloons which have inherent elastic properties, respiratory bellows which can expand and contract in response to changes in volume, a lung simulator device that can move air in and out of the lung to accommodate volume changes during ventilation, a two-way syringe system that directly instills and removes, and / or the use of elastic material used in production of the airway and / or chamber walls. Similarly, the system described herein is also capable of simulating other ranges of lung compliance associated with disease states that may eitherAttv. Docket No. 206030-0293-00WG increase compliance, as occurs in emphysema, or decrease it, as is characteristic of interstitial lung diseases and acute lung injury.
[0082] In addition to these three key components of the invention, there are two additional components that interact with the artificial ventilated lung exposure system to increase its utility and functional capacities including: 1) integrated access ports that can be used for monitoring internal chamber conditions that may include, but are not limited to, temperature, relative humidity, pressure, gas composition, concentration of total or specific volatile organic compounds, particle number concentrations, particle size distributions, particle mass distributions, and particle composition; and 2) the creation of a sterile environment that will support the culture and exposure of cells and tissues to the environment within the lung exposure chamber during the inhalation of a test exposure and during ongoing breathing. Creation of this form of culture environment involves the introduction of mechanisms for sterile filtration so that introduced air, gases and aerosols do not carry unanticipated infectious agents and the capacity to clean, sterilize and isolate components that would interact with the contained cell cultures.
[0083] Collectively, the three (3) key functional components and described additive features of the disclosed invention empower this novel artificial ventilated lung exposure system to recreate lung inhalation exposures in the setting of ongoing breathing in an anatomically and physiologically relevant manner that is unique from all other inhalation exposure systems. The system recreates (1) lung shape, volume and the presence of anatomically precise 3D-printed upper and lower airway structures that empower the investigation of airflow characteristics, aerosol composition, and aerosol deposition at desired region-specific levels throughout the lung; (2) the process of continuous ventilation (breathing), allowing for adjustable features of the rate, timing and volume of inhalation and exhalation, which create a dynamic mixing and evacuationAttv. Docket No. 206030-0293-00WD of inhaled particles and gases that fundamentally change exposure levels in a manner fundamentally different than exposure systems based on fixed dilutions and flow rates; (3) the warm and humid lung environment and other environmental features including gas composition and volume-associated pressure changes that can directly alter the features of inhaled particles and their patterns of distribution and deposition; and (4) provides the tools and approaches required to monitor and investigate the nature of modeled intrapulmonary exposures at various region-specific levels and to test their impact on cultured cells and tissues that can be exposed within the lung chamber. Consequently, this system can simulate diverse inhalation scenarios involving various aerosols, such as repetitive vaping of electronic cigarettes, the inhalation of medical aerosols, or the inhalation of reproduced atmospheric and occupational exposures and simultaneously support their impact on intrapulmonary exposures or toxicity as well as assess the impact of adaptive human ventilatory responses on internal lung exposures. There is no existing device that enables these range of features and this system demonstrates the potential to become a widely adopted tool for assessing aerosol exposures and toxicology.
[0084] Referring now to FIG. 1, shown is an exemplary artificial lung exposure system (100) according to one aspect of the present invention. In some embodiments, system 100 comprises an incubator or environmental control chamber (110) comprising at least one port to allow the ingress and egress of ventilation tubing and cables (120 / 122), and a removable internal lung exposure chamber (130) comprising a plurality of walls configured to represent the shape and volume of a lung or pair of lungs, that is positioned within incubator 110 in fluid connection with at least one port to allow a connection to ventilation. System 100 further comprises a 3D airway model (150) connected to a port in the lung exposure chamber (130) and in fluid connection with the ventilation system (120 / 122). In some embodiments, an upper airway portion of the 3DAttv. Docket No. 206030-0293-00WG airway model (152) is at least partially positioned within chamber 1 10 (outside of the lung exposure chamber) and is connected to or passes through the port into the lung exposure chamber. In some embodiments, a lower airway portion of the 3D airway model (154) is contained withing the lung exposure chamber and in fluid connection with its port and the ventilation system. In some embodiments, system 100 further comprises one or more test lung balloons (160) in fluid connection with the lung exposure chamber 130. In some embodiments, system 100 further comprises at least one, and often multiple, sensors (180) positioned within chamber 130 and / or airway model 150 to monitor environmental and exposure conditions within the lung exposure chamber 130. It should be appreciated that each fluidly connected component of system 100 is connected via methods, tubes, conduits, connectors, valves, or the like, known by one of ordinary level of skill in the art.
[0085] In some embodiments, at least one port in system 100 comprises an inspiratory port (120), an expiratory port (122), and at least one sampling port (124). In some embodiments, at least one sampling port 124 comprises a first and second sampling port positioned posterior and anterior to airway model 150. In some embodiments, the ventilation tubing (120, 122) comprises one or more valves in fluid connection to adjust the flow of gas through the ventilator circuit. For example, one or more valves may be positioned between inspiratory port 120 and expiratory port 122, wherein the valve is configurable between an inhalation and exhalation configuration.
[0086] In some embodiments, system 100 further comprises a gas supply (194), attached to a ventilator (182), and a heater / humidifier (184), each in fluid connection with the inspiratory ventilator tubing (120) and configured to provide a controllable air flow of conditioned air to the airway model and lung exposure chamber. In some embodiments, system 100 further comprises an agitator positioned inside chamber 130, for agitating the air within the chamber to mix and / orAttv. Docket No. 206030-0293-00WD suspend inhaled particulates. In some embodiments, system 100 further comprises a fdter fluidly connected with any flow path, port or component of the system. In some embodiments, the fdter is a sterile fdter or a particulate capturing fdter. In some embodiments, system 100 further comprises any valve, coupling, fitting, or clamp known by one of ordinary level of skill in the art. In some embodiments, any valve of system 100 is a one-way valve, a two-way valve, or a pressure relief valve, or an electronically controlled valve.
[0087] Now referring to FIG. 2, shown are exemplary ventilation flow paths through system 100 according to aspects of the present invention. During a simulated positive pressure inhalation or inspiration (left), turbulent air flow generated from a ventilator (182) passes through inspiratory ventilator tubing (120) and enters the airway model 150 (Left). Next, as air flow travels through each successive airway generation in model 150 (middle) it slows and transitions to laminar air flow based on the features of the 3D airway model. As the inhaled breath exists the final lower airway generation 154 and enters the lung exposure chamber 130, the resulting pressure changes force the inhaled lung volume to enter into and expand the test lung balloon(s) 160 that are in fluid connection. The test lung balloon(s) are elastic in nature, each type designed with a specific compliance, and as they expand the pressure change within the lung exposure chamber 130 is controlled / limited. In addition, when the inhaled breath ends, the stored elastic recoil energy within the test lung balloon(s) 160 result in a reversal of airflow to create an exhalation (right). As shown in this embodiment, two test lung ballons are attached to promote symmetric flow through both the right and left lung airways and to control the intrapulmonary pressure excursions within ranges associated with normal breathing. During the exhalation phase, the inspired volume exists the test lung balloons 160, enters back into the lung exposure chamber 130, then into the airway model 150, and is exhaled through the exhalation tubing 122.Attv. Docket No. 206030-0293-00WG
[0088] According to other aspects of the present invention, the driving forces for airflow during ventilation may be reversed. Rather than positive pressure ventilation, which is detailed in FIG. 2, the lung exposure chamber may also be ventilated by negative pressure. In such an embodiment, there is no need for a ventilator (182) or test lung ballon(s) (160), but a system that produces alternating negative and positive pressures is used to replace the test lung ballons and is in fluid connection with the lung exposure chamber. Systems capable of generating alternating negative and positive pressures include respiratory bellows, a two-way syringe system, a controlled combination of vacuum pumps and blowers, a formal lung breath simulation device, or the like as would be known by one of ordinary level of skill in the art. In this setting, when a negative pressure is applied to the lung exposure chamber 130, a volume of air is drawn through inhalation tubing 120, then through the 3D airway model 150 and into the chamber. At the end of inhalation, a positive pressure of equal magnitude and time is applied to the lung exposure chamber that drives an equal volume of air back through the 3D airway model 150 and out through the exhalation tubing 122. In either embodiment, a set volume of air (a breath) is delivered into the exposure chamber during inhalation and then exhaled, recreating the process of ventilation.
[0089] Referring now to FIG. 3, shown is an exemplary setup for using the artificial ventilated lung exposure system to generate and test an intrapulmonary aerosol exposure resulting from a puff generated from an electronic nicotine delivery system (ENDS; also referred to as an electronic cigarette or e-cig device). In this embodiment, system 100 further comprises a programmable aerosol generator (190) that is in fluid connection with a source of e-cig liquid (192), a compressed air source (194), a delivery tube (196) and a three-way valve (198). An external power source and electrical control panel is used to intermittently heat the aerosol-Attv. Docket No. 206030-0293-00WG generating wire within the aerosol generating device. By controlling the flow rate from the compressed air source (194) and the control valve (198), the heated aerosol generating wire will vaporize the liquid and carry a defined e-cig “puff’ into the inspiratory tubing (120). When appropriately timed with the breath of conditioned air delivered by the ventilator (182) and heated humidifier (184), the puff of e-cig aerosol is inhaled into the lung exposure chamber (130) according to the flow pattern previously described. Fundamental features of the current invention allow the features, volume, and timing of the simulated e-cig puff to be controlled. Furthermore, exactly how the generated e-cig puff is coordinated with the inhaled breath and the breathing pattern matters (the flow rates, inspiratory time, respiratory rate, tidal volumes, and other features associated with ventilation) and can be independently controlled as required for any given scenario that is being tested. In conjunction with this, the anatomic features and size profile of the 3D airways (150) and the lung exposure chamber itself (130) can all be controlled as needed for the specified test scenario. The adaptability designed into the different components of the current invention is key for successful modeling in which a generated puff, of a given volume and features, is admixed with a given breath and delivered through the defined airways and into the lung chamber, each with their own defined features. After a puff is inhaled, the aerosol exposure within the lung can be serially diluted and exhaled due to the ongoing breathing of fresh air. The nature of the e-cig puff and the serial admixing, dilution, and clearance of the inhaled aerosol puff as it travels through the various lung compartments, along with changes in temperature, humidity, pressure, airflow patterns and airway deposition that occur within each lung region, all contribute to the ultimate intrapulmonary lung exposure. In other embodiments of the current invention, the introduction of a puff of e-cig aerosol as described in this example, may be replaced by other aerosol exposures of interest such as indoor and outdoor air pollution,Attv. Docket No. 206030-0293-00WG aerosols generated from use of tobacco and cannabis products, therapeutic drugs delivered by the aerosol route, natural and manmade bioaerosols, aerosolized microplastics and nanomaterials, and like exposures that would be of interest for understanding their exposure levels, biological, medicinal or toxic effects on the lungs. In another embodiment, an environmental exposure may be inhaled directly from the air or from an exposure chamber in which an exposure condition has been created.
[0090] At any point during the simulated inhalation or exhalation, sampling of the intrapulmonary conditions may be performed via port 124 for gas phase, particle phase, and / or environmental measurement, analysis, or the like. Further, one or more signals via at least one sensor 180 may be captured and recorded during the simulated breathing. In some embodiments, sensor 180 may be any sensor known in the art, including, but not limited to, an environmental sensor, a pressure sensor, a temperature sensor, a humidity sensor, a gas sensor, a volatile organic compound sensor, or other form of biologic or physical sensor. In some embodiments, system 100 further comprises the addition of aerosol monitoring and analysis equipment including a Scanning Mobility Particle Spectrometer (SMPS; 170), an Aerodynamic Particle Sizer (APS; 172), and a water-based condensation particle counter (WCPC, 174) each in fluid connection with monitoring port 124, and configured to analyze the aerosol features of intrapulmonary air in different lung regions of interest that are produced during simulated puffing and breathing. In some embodiments, alternative monitoring equipment that is capable of measuring other features of the inhaled particulates and gases would be appropriate including VOC monitors, various mass spectrometer systems and the like. It should be appreciated that with this configuration, monitoring equipment may be alternatively placed both upstream (via inspiratory path 120) or downstream (via expiratory path 122) of the lung exposure chamber inAttv. Docket No. 206030-0293-00WG order to compare aerosol features of the sample that is delivered to the lung to that occurring within a given lung region, and to the generated second-hand exposure that occurs from exhalation. These different measurements can therefore be used to calculate important aspects of inhalation exposure such as the particle deposition fraction and the exhaled fraction.
[0091] Referring now to FIG. 4, depicts an illustrative computer architecture for a computer 2800 for practicing the various embodiments of the invention. The computer architecture shown illustrates a conventional personal computer, including a central processing unit 2850 (“CPU”), a system memory 2805, including a random access memory 2810 (“RAM”) and a read-only memory (“ROM”) 2815, and a system bus 2835 that couples the system memory 2805 to the CPU 2850. A basic input / output system containing the basic routines that help to transfer information between elements within the computer, such as during startup, is stored in the ROM 2815. The computer 2800 further includes a storage device 2820 for storing an operating system 2825, application / program 2830, and data.
[0092] The storage device 2820 is connected to the CPU 2850 through a storage controller (not shown) connected to the bus 2835. The storage device 2820 and its associated computer- readable media provide non-volatile storage for the computer 2800. Although the description of computer-readable media contained herein refers to a storage device, such as a hard disk or CD- ROM drive, it should be appreciated by those skilled in the art that computer-readable media can be any available media that can be accessed by the computer 2800.
[0093] By way of example, and not to be limiting, computer-readable media may comprise computer storage media. Computer storage media includes volatile and non-volatile, removable and non-removable media implemented in any method or technology for storage of informationAttv. Docket No. 206030-0293-00WG such as computer-readable instructions, data structures, program modules or other data.Computer storage media includes, but is not limited to, RAM, ROM, EPROM, EEPROM, flash memory or other solid state memory technology, CD-ROM, DVD, or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium which can be used to store the desired information and which can be accessed by the computer.
[0094] According to various embodiments of the invention, the computer 2800 may operate in a networked environment using logical connections to remote computers through a network 2840, such as TCP / IP network such as the Internet or an intranet. The computer 2800 may connect to the network 2840 through a network interface unit 2845 connected to the bus 2835. It should be appreciated that the network interface unit 2845 may also be utilized to connect to other types of networks and remote computer systems.
[0095] The computer 2800 may also include an input / output controller 2855 for receiving and processing input from a number of input / output devices 2860, including a keyboard, a mouse, a touchscreen, a camera, a microphone, a controller, a joystick, or other type of input device. Similarly, the input / output controller 2855 may provide output to a display screen, a printer, a speaker, or other type of output device. The computer 2800 can connect to the input / output device 2860 via a wired connection including, but not limited to, fiber optic, Ethernet, or copper wire or wireless means including, but not limited to, Wi-Fi, Bluetooth, NearField Communication (NFC), infrared, or other suitable wired or wireless connections.
[0096] As mentioned briefly above, a number of program modules and data files may be stored in the storage device 2820 and / or RAM 2810 of the computer 2800, including anAttv. Docket No. 206030-0293-00WG operating system 2825 suitable for controlling the operation of a networked computer. The storage device 2820 and RAM 2810 may also store one or more applications / programs 2830. In particular, the storage device 2820 and RAM 2810 may store an application / program 2830 for providing a variety of functionalities to a user. For instance, the application / program 2830 may comprise many types of programs such as a word processing application, a spreadsheet application, a desktop publishing application, a database application, a gaming application, internet browsing application, electronic mail application, messaging application, and the like. According to an embodiment of the present invention, the application / program 2830 comprises a multiple functionality software application for providing word processing functionality, slide presentation functionality, spreadsheet functionality, database functionality and the like.
[0097] The computer 2800 in some embodiments can include a variety of sensors 2865 for monitoring the environment surrounding and the environment internal to the computer 2800. These sensors 2865 can include a Global Positioning System (GPS) sensor, a photosensitive sensor, a gyroscope, a magnetometer, thermometer, a proximity sensor, an accelerometer, a microphone, biometric sensor, barometer, humidity sensor, radiation sensor, or any other suitable sensor.
[0098] In some aspects of the present invention, software executing the instructions provided herein may be stored on a non-transitory computer-readable medium, wherein the software performs some or all of the steps of the present invention when executed on a processor.
[0099] Aspects of the invention relate to algorithms executed in computer software. Though certain embodiments may be described as written in particular programming languages, or executed on particular operating systems or computing platforms, it is understood that the systemAttv. Docket No. 206030-0293-00WG and method of the present invention is not limited to any particular computing language, platform, or combination thereof. Software executing the algorithms described herein may be written in any programming language known in the art, compiled, or interpreted, including but not limited to C, C++, C#, Objective-C, Java, JavaScript, MATLAB, Python, PHP, Perl, Ruby, or Visual Basic. It is further understood that elements of the present invention may be executed on any acceptable computing platform, including but not limited to a server, a cloud instance, a workstation, a thin client, a mobile device, an embedded microcontroller, a television, or any other suitable computing device known in the art.
[0100] Parts of this invention are described as software running on a computing device. Though software described herein may be disclosed as operating on one particular computing device (e.g. a dedicated server or a workstation), it is understood in the art that software is intrinsically portable and that most software running on a dedicated server may also be run, for the purposes of the present invention, on any of a wide range of devices including desktop or mobile devices, laptops, tablets, smartphones, watches, wearable electronics or other wireless digital / cellular phones, televisions, cloud instances, embedded microcontrollers, thin client devices, or any other suitable computing device known in the art.
[0101] Similarly, parts of this invention are described as communicating over a variety of wireless or wired computer networks. For the purposes of this invention, the words “network”, “networked”, and “networking” are understood to encompass wired Ethernet, fiber optic connections, wireless connections including any of the various 802.11 standards, cellular WAN infrastructures such as 3G, 4G / LTE, or 5G networks, Bluetooth®, Bluetooth® Low Energy (BLE) or Zigbee® communication links, or any other method by which one electronic device isAttv. Docket No. 206030-0293-00WG capable of communicating with another. Tn some embodiments, elements of the networked portion of the invention may be implemented over a Virtual Private Network (VPN).EXPERIMENTAL EXAMPLES
[0102] The invention is now described with reference to the following Examples. These Examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these Examples, but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
[0103] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present invention and practice the claimed methods. The following working examples, therefore, specifically point out exemplary embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.Example 1 : Construction of an Artificial Ventilated Luna Exposure System to Analyze and Test Human Exposures to e-cig aerosols.
[0104] The human respiratory system functions as a crucial interface connecting the external environment to the systemic circulation. The respiratory epithelium is continuously exposed to an expanding array of airborne substances from various sources, including indoor and outdoor air pollution, tobacco smoke, electronic cigarettes (e-cigs) aerosols, bioaerosols, microplastics, and engineered nanomaterials [Keswani et al. NEJM Evidence, 1(7): EVIDra2200068, 2022; Wang et al. Science, 373(6558): eabd9149, 2021; Dinakar et al. NewAttv. Docket No. 206030-0293-00WGEngland Journal of Medicine, 375(14): 1372-1381, 2016; Sridharan et al. Journal of Hazardous Materials, 418: 126245, 2021; Patel et al. Environmental Chemistry Letters, 19(6): 4253-4274, 2021], Exposure to harmful airborne substances substantially contributes to global morbidity and mortality resulting from associated respiratory and cardiovascular diseases [Li et al. Particle and Fibre Toxicology, 19(1): 67, 2022; WHO. Global Health Estimates, 2024], Therefore, it is of particular interest in toxicology, pulmonary medicine and environmental health to assess the inhalation exposure and subsequent health effects of various airborne substances. However, obtaining toxicology results that are representative of humans has been a longstanding challenge for both traditional in vivo and in vitro tests, as well as new methodologic approaches [Movia et al. Frontiers in Bioengineering and Biotechnology, 8: 549, 2020; Yang et al. Environmental Pollution, 268: 115861, 2021], In most circumstances, gas or aerosol samples of interest are collected into large room temperature chambers, under static conditions, and analyzed for their composition, size and mass distributions and physiochemical properties. However, experimental factors such as dilution ratio, temperature, and humidity substantially influence particle size distributions through aerosol dynamics, including coagulation, condensation, evaporation, and hygroscopic growth [Sosnowski et al. Frontiers in Physiology, 9: 853, 2018; Son et al. Chemical Research in Toxicology, 33(2): 343-352, 2020], Consequently, it is uncertain whether aerosol characteristics measured under different conditions accurately represent those in human lungs. It is also common practice for gases and particles from inhalation aerosols to be trapped and concentrated within culture media to produce ACM, which is then added to cells or tissues in culture to evaluate toxicity. In other approaches, aerosols are variably diluted and allowed to flow onto / over cells or tissues in culture to evaluate toxicity under ALI conditions. However, such approaches similarly fail to replicate “intrapulmonary exposures” as they occur in theAttv. Docket No. 206030-0293-00WD human lung and therefore fail to adequately represent lung epithelial exposures, inhalation exposure risks and patterns of toxicity.
[0105] Disclosed herein is an exemplary artificial lung system that replicates intrapulmonary exposures in several novel aspects by integrating key aspects of lung anatomy, physiology, ventilation, environmental conditions, airway biology and inhalation behavior into a more physiologically and biologically relevant inhalation exposure system. This disclosed invention is intended for two broad uses, amongst many others that would be considered by someone experienced in the art and familiar with the embodiments described here-in. One use would be to recreate intrapulmonary exposure conditions in a manner that will allow assessment of the aerosol features and characteristics as they exist in specific regions of the lung that would include the upper airway, large and small conducting airways, and the respiratory zones of the lung. Another use would be to create a system in which cells, whole lung epithelial or whole tissue cultures could be repeatedly exposed under naturalistic air-liquid interface (ALI) conditions to these region-specific exposure conditions to assess their toxicity and biologic effects.
[0106] For the embodiment described here, the three key components have already been detailed (FIGs. 1-4) which include 1) an airtight lung exposure chamber that reproduces lung anatomy in terms of the conical shape and volume of the overall lung and the presence of 3D modeled airway structures through which ventilated air travels; 2) the integration of a ventilatory component to simulate the dynamic processes involved in breathing that includes an inhalation phase that could be synchronized with a e-cig puffing device and capable of delivering a selected tidal volume, an exhalation phase and a control mechanism for adjusting the delivered volumes and respiratory rate; and 3) mechanisms for environmental control of features that includeAttv. Docket No. 206030-0293-00WG temperature, relative humidity, intra-chamber gas composition and volume-associated pressure changes (compliance) within the lung exposure chamber.
[0107] To fulfill the criteria for component 1, an exemplary ventilated artificial lung exposure chamber was created using inert polycarbonate sheet material that was fabricated using a combination of cold-welding and epoxy resin sealing to create a gas-tight 3D exposure chamber that approximates the conical shape and average lung volume (6 L) of an adult male (47-y ear-old, 185 cm high, and 80 kg) at the end of inhalation. This volume was calculated as the functional residual capacity (FRC) plus 50% of the inspiratory capacity (IC) using the Global Lung Function Initiative (GLI) calculator [Hall et al. European Respiratory Journal, 57(3): 2000289, 2021], A replica of human airways was prepared by high-resolution 3D printing (Form 3, Formlabs, Inc., USA) that employed a transparent Flexible 80A resin (Formlabs, Inc) capable of expanding and contracting in response to each breath. An upper airway component, representing the mouth, oral pharynx and larynx, was installed upstream of the lung exposure chamber and connected to it through a central apical entry port. The upper airway geometry was obtained from a computed tomography (CT) scan of a 47-y ear-old healthy male volunteer, 174 cm in height and 78 kg in weight, with no history of respiratory diseases [Banko et al.Experiments in Fluids, 56: 117, 2015; Zhang et al. Journal of Aerosol Science, 53: 40-60, 2012], The developed tracheobronchial (TB) airway model adopted the shape of the TB airways at the end of inhalation, set at the residual volume plus 45% of the vital capacity; this was calculated on the basis of a 500 mb normal breath using the Global Lung Function Initiative calculator [Stanojevic et al. European Respiratory Journal, 50(3): 1700010, 2017], The resulting 3D printed airway structure consisted of a total of 375 individual airway segments, including 188 distal terminal airways. The furthest terminal airway was at generation 13 (G13), representative of pre-Attv. Docket No. 206030-0293-00WG terminal bronchioles, and exhibited a hydraulic diameter down to 1 .02 mm. The architecture of the TB tree was reconstructed with realistic anatomical features using Lung4Cer based on a stochastic algorithm [Kitaoka et al. EMBC Conference Proceedings, pp. 453-456, 2013], This approach resulted in a high-resolution airway model that approximated the anatomy and physiology of the real human lung while accounting for the appropriate size and geometry of the airways during breathing and for the target age, gender and size of a selected average male.
[0108] To fulfdl the criteria for component 2, a volume-controlled ventilator (EPV100, Allied Elealthcare Inc., USA) was attached to a single limb ventilator circuit (Model L599-130, Allied Healthcare Products Inc., USA). This ventilator circuit employed a duckbill one-way valve and low resistance exhalation port to isolate and control both the inspiratory and expiratory phases of ventilation. The ventilator circuit connected directly to the upper airway mouth through an adaptor. A compressed gas source and attached pressure regulator were used to generate the driving force for each inhalation. In addition, two elastic test balloons (Venti Plus, Maxtec LLC., USA) were symmetrically attached to each side of the lung chamber, expanding in response to the positive pressure during inhalation and then spontaneously contracting to ‘exhale’ due to their intrinsic elasticity. When used in combination like this, the ventilator and the test balloons are capable of mimicking lung volume changes during breathing (e.g., tidal volume). Their compliance was specifically tuned to regulate intrapulmonary pressures within normal ranges (0 to 20 cmHzO). Ventilator settings for this embodiment included an adjustable inspiratory time (0 to 2 s), tidal volume (200 to 1200 mL), and respiratory rate (8-20 breaths per minute; BPM). A typical resting breathing pattern for a normal adult male was set at 10 BPM, 2 second inspiratory time and a 480 mL / breath. This resulted in a 6-s breath cycle composed of 2-s inhalation, 2-s exhalation, and 2-s pause before the next breath, as illustrated in FIG. 5.Attv. Docket No. 206030-0293-00WG
[0109] In this specific example, the goal was to study the exposure and toxicity resulting from e-cig vaping. As such, this embodiment included an integrated e-cig puff generator that connected to the ventilation circuit as shown in FIG. 3, item 192. A Virginia Tobacco-flavored JUUL pod containing 5% nicotine salt with a polyethylene glycol / vegetable glycerol (PG / VG) ratio at 30 / 70 was employed as the e-liquid for experimental testing [Ranpara et al. Frontiers in Public Health, 9, 2021; Talih et al. Tobacco Control, 28(6): 678-680, 2019; Erythropel et al. American Journal of Preventive Medicine, 57(3): 425-427, 2019], The e-cig puffing apparatus was composed of a HEPA-filtered compressed air source, a JUUL pod holder (Automate Scientific Inc., USA), a programmable electronic controlling board and a DC supply to operate the e-cig device and deliver 3.7 V to its heating coil [Ma et al. Environment & Health, 1(5): 315- 323, 2023; Li et al. Aerosol Science and Technology, 54(11): 1270-1281, 2020], To coordinate e-cig puffing with the ventilator cycle, the control board was set to deliver e-cig aerosols during the final 2 seconds of a breath cycle when there was no flow in the exposure chamber. Each puff was generated by energizing the heating coil in combination with sending a 1 L / min flow rate of air through the device. Coil heating occurred for a 2 second puff duration, which created a 33 ml e-cig aerosol puff volume that was delivered to the mouth and inhaled into the lung with the next full breath. This puff and inhale topography recreated the reported vaping topography most often observed for those using fourth generation of e-cig devices [Prasad et al. International Journal, 8(12): 366, 2022; Robinson et al. PLOS ONE, 11(10): e0164038, 2016], A control valve, between the e-cig apparatus and inspiratory limb of the ventilator, was closed after each puff to prevent additional air flow from the aerosol device from entering the lung.
[0110] To fulfdl the criteria for component 3, the temperature and relative humidity (RH) within the lung exposure chamber were controlled primarily by integrating a clinical-gradeAttv. Docket No. 206030-0293-00WG heating and humidification device (MR730, Fisher & Paykel Healthcare Ltd., New Zealand) into the inspiratory limb of the ventilator circuit. As such, each breath delivered by the ventilator passed through the heat and humidification exchanger on its way to the lung exposure chamber. A second heating source was also employed. For this, the lung exposure chamber was housed within a temperature-controlled test chamber (0 °C to 70 °C, model KBF-115, Binder GmbH., Germany). These two approaches, working in tandem, enabled the independent control of the temperature (normal range 22 to 37°C) and RH (normal range 2 to 88+3%) within the lung exposure chamber and simultaneously prevented the formation of any condensation within the model. Temperature and RH were continuously monitored using a probe (USB-VOCIOO, Dracal Technologies, Inc., Canada) inserted through an apical port. In a similar manner, pressure within the lung exposure chamber was carefully regulated by the interaction of two components - the driving pressure generated by the ventilator during each breath and the presence of two elastic test balloons (Venti Plus, Maxtec LLC., USA) attached to apposing side ports on the exposure chamber. In this manner, as detailed in FIG. 2, each breath delivered by the ventilator would enter the chamber in a symmetric pattern. As pressure increased within the chamber, the elastic test balloons would symmetrically-expand and therefore modulate pressure changes and flow patterns. Then, at the end of inhalation, the inherent elasticity of the test balloons allowed them to contract and generate the exhalation force for each breath. Their compliance was specifically tuned to regulate intrapulmonary pressures within normal ranges (0 to 20 CIT1H2O). An integrated digital manometer (TK277PLUS, Tekoplus Ltd., China) tracked pressure changes within the lung exposure chamber in real time during each breath as demonstrated in FIG. 5. Atmospheric gas composition was also controlled so that the relative partial pressures for CO2, O2 and N2 were maintained at levels consistent with the average alveolar lung environment. This wasAttv. Docket No. 206030-0293-00WD achieved by using a specialized pulmonary function gas cylinder (Airgas, Inc., USA) containing 5% CO2, 21% O2, balance N2, as the compressed gas source that drove the ventilator breaths.
[0111] In order to investigate intrapulmonary vaping exposure, this embodiment included chamber monitoring ports that were attached to aerosol monitoring equipment as detailed in FIG.3. The particle number concentrations (PNCs) in the lung chamber were measured in real time using a nano water-based condensation particle counter (N-WCPC, Model 3788, TSI, Inc., USA). Dilution using compressed air was applied to ensure that the PNCs were within the measurable range of the W-CPC. The area under the curve exposures over time and decay rates of particles under different breathing patterns were also calculated from the raw data using established methods [Li et al. Aerosol Science and Technology, 54(11): 1270-1281, 2020], The size distributions of e-cig aerosols were measured by employing a Scanning Mobility Particle Sizer (SMPS, Model 3936, TSI, Inc., USA) and an Aerodynamic Particle Sizer (APS, Model 3321, TSI, Inc., USA). The measuring modes for the SMPS and APS were optimized and covered a size range of 13 to 445 nm for the SMPS (electric mobility diameter) and 542 nm to 20 pm for the APS (aerodynamic diameter); these ranges encompassed the majority of the particles emitted from e-cigs.
[0112] In order to investigate exposure-related epithelial toxicity, this embodiment of the ventilated artificial lung exposure system was also set up to facilitate studies under sterilized conditions. The exposure chamber and associated tubing, connectors and test lungs were routinely sterilized prior to use through a combination of rinsing with 70% ethanol, controlled ozone sterilization, standard sterile handling techniques and the use of inline antimicrobial filters for the ventilator and compressed gas sources. Disposable ventilator circuits and filters were replaced by new sterilized components prior to each set of experiments. The lung exposureAttv. Docket No. 206030-0293-00WG chamber was also created with a removable bottom plate that allowed the model to be opened so that culture plates could be inserted for exposure studies (FIG. 6). To generate sterile cultures of normal human bronchial epithelial (NHBE) cells, commercial progenitor cells were obtained from a healthy donor (CC-2540S, Lonza, Inc., USA), expanded and then differentiated into HBEC layers under ALI model conditions. Briefly, stock NHBE cells were expanded in submerged culture using PneumaCult-Ex Plus Medium (05040, Stemcell Technologies, Inc., CA), harvested by washing with Dulbecco’s phosphate-buffered saline (DPBS) without calcium and magnesium (Cytiva LLC., USA) and then dissociated using a cell dissociation kit (05426, Stemcell Technologies, Inc., CA). The cells were washed and resuspended in PneumaCult-Ex Plus Medium, and cell counts were performed. In total, 1.1 x 105 cells in 0.5 mL of PneumaCult- Ex Plus Medium were plated in each Transwell insert sized for 12-well plates (3513, Corning, Inc., USA), and 1 mL of the same medium was added to the basal chamber. After 2-3 days, when confluence was reached, the media from both the basal and apical chambers were removed, and 1 mL of PneumaCult-ALI Maintenance Medium (05001, Stemcell Technologies, Inc., CA) was added to the basal chamber to create an ALI culture. Basal media were changed every 2 days. After 2 weeks of ALI culture, mucus was removed from the apical surface by gently washing the cells with DPBS. After 8 weeks of ALI culture, histological imaging using hematoxylin and eosin (H&E) staining confirmed the differentiated pseudostratified mucociliary epithelium and wells at this stage were inserted into the chamber for up to 2 days of exposure to repeated puffing sessions of e-cig aerosols to directly assess toxicity. NHBE cultures differentiated in this manner can be maintained for months to years in culture and for these studies were used between 8-16 wks from initial expansion.Attv. Docket No. 206030-0293-00WG
[0113] This physical embodiment of the artificial ventilated lung exposure system was used as the basis for all subsequent experimental examples.Example 2: Active ventilation results in dynamic alterations to intrapulmonary exposures.
[0114] If the underlying hypotheses for this invention are correct, one would expect that intrapulmonary exposures are dependent on the magnitude of the inhaled e-cig exposure (the size and number of puffs), the volume and physical features of the lung exposure chamber, and the ongoing process of lung ventilation (i.e breathing). As such, exposure using the described system is predicted to be a very dynamic process in which a small puff of e-cig aerosol is delivered into the mouth and then diluted within the volume of the next breath as it is inhaled. A breath of 480 ml, delivered over a 2 sec inspiratory time, creates a proximal flow rate of 14.4 1pm that is associated with very turbulent air flow and mixing at the level of the trachea. As the breath is delivered deeper into the lung it is further diluted within the larger volume of lung available for gas exchange. In the presence of the TB tree, air flow is also progressively slowed and transformed into laminar flow due to the logarithmic increase in cross-sectional of the branching airways. By the time the inspired breath reaches the level of airway G13, the fast turbulent airflow from the trachea transitions into slow laminar airflow [Zarei et al. Journal of NonEquilibrium Thermodynamics, 38(2): 119-140, 2013] before being distributed throughout the lung chamber. The impact of conducting airways on air flow was assessed visually in our lung exposure model by comparing the airflow pattern when delivered into the chamber through just the tracheal airway or after passing through the entire printed airway structure through G13 (FIG. 7). To further assess airflow profiles within the modeled 3D-printed airways, we conducted computational fluid-particle dynamics (CFPD) simulations using the TB tree architecture fromAttv. Docket No. 206030-0293-00WG our model and flow rates determined for a typical resting breathing pattern (10 BPM, 480 mL per breath). CFPD modeling revealed that the peak airflow velocity during inhalation (FIG. 8A) gradually decreases from the upper to lower airways as the total cross-sectional areas increase. The averaged turbulence kinetic energy (TKE) was calculated at different cross-sections along two selected routes in each lung lobe (FIG. 8B). The overall decreasing trend of TKE from the trachea to distal airways confirms that the turbulence present in the central airway region gradually transitions to laminar flow as it passes through each subsequent airway generation. As a result, this model can uniquely recreate the regional air flow rates and patterns that are responsible for the regional deposition of inhaled particles within the lung.
[0115] Once a vaping aerosol is fully inhaled, the majority of delivered particles remain suspended in air. In this setting, given the intermittent nature of vaping, ongoing breathing of fresh air would then be expected to slowly dilute and clear (exhale) the retained vaping aerosols. To directly test this hypothesis, we designed a standard 4-puff vaping cycle that approximates a realistic average vaping session for users of a 4th generation pod device [Rabenstein et al. Toxics, 11, 2023; Vargas-Rivera et al. Tobacco Control, 30(4): 399, 2021], In other words, a 33 ml puff of e-cig aerosol was delivered to the mouth every 60 seconds until 4 puffs had been delivered. To simplify the focus, initial studies were performed in a standard room environment (38% RH, 25°C) and with only the tracheal airway in place. Ongoing ventilation was set to resting conditions at 10 BPM and 480 ml. PNCs within the lung chamber were monitored in real time (1 sec intervals) throughout the 4-puff vaping cycle and for an additional 10 minutes after the last puff. As predicted and shown in FIG. 9, the PNCs measured in real time over a typical vaping session demonstrated a progressive accumulation of e-cig particles within the lung chamber after each puff (of the 4-puff vaping session), as well as the gradual removal of inhaledAttv. Docket No. 206030-0293-00WG particles between the puffing intervals and after the last puff. In the presence of ventilation, the cyclical pressure changes within the chamber (as detailed in FIG. 5) create a fluctuating pattern of real-time PNC readings that reflect pressure-induced changes in flow rate with each breath. Control experiments established that the mean PNC, between each peak and valley, corresponded with the running average chamber PNC (dotted line). Experimental figures and date analyses were generated using these mean PNC values. In order to better understand the impact of ventilation on inhaled particle exposures within the lung model, a static condition was also studied using the same artificial lung system with the following modifications: Only one breath was administered from the ventilator with each puff in order to deliver the e-cig aerosol into the lung. The ventilator was turned off between vaping puffs and after the 4th puff (during the decay period). A magnetic stirrer was used to maintain the suspension and mixing of the e- cig aerosols within the chamber.
[0116] The results obtained from the comparison of a static chamber to one that experienced ongoing ventilation are striking. As demonstrated in FIG. 10, the peak PNCs within the lung chamber increased in a step-wise manner as each additional puff of aerosols was inhaled into the exposure model, regardless of the presence or absence of ongoing ventilation. However, while the peak PNC after the 4th puff reached 4.32 ± 0.91 x 106 # / cm3(95% CI, N=3) under static conditions, it only reached 2.61 ± 0.64 x 106 # / cm3(95% CI, N=3) in the presence of a resting pattern of ventilation (10 BPM and 480 mL / breath). This direct comparison indicated an average 40% reduction in the peak PNCs primarily due to the serial dilution and exhalation of particles from ongoing breathing during the puffing intervals. Ongoing breathing also substantially impacts on the decay rate of particles after the last e-cig puff, leading to a much faster decay rate (31.5 ± 2.9 h-1, 95% CI) as compared to the static condition (7.6 ± 2.4 h-1, 95% CI). As a result,Attv. Docket No. 206030-0293-00WG the introduction of a resting breathing pattern led to lower intrapul mon ary exposures compared to those under the static condition. This amounted to an overall 70% reduction in the AUC for PNCs within the lung chamber. Increasing the minute ventilation (tidal volume x respiratory rate), by serially changing respiratory rates (10 or 15 BPM) and tidal volumes (480 or 720 mL) resulted in a proportional decrease in intrapulmonary exposures to e-cig aerosols (FIGs. 11 A & 1 IB). When the respiratory rate was held constant (10 BPM) but the tidal volume increased by 50% (from 480 to 720 mL / breath), the peak PNC also decreased by approximately 25% (1.96 ± 0.67 * 106 # / cm3, 95% CI) and the particle decay rate increased approximately 1.44-fold (45.3 ± 2.6 h-1, 95% CI). When the tidal volume was then held constant at 720 mL / breath and the respiratory rate increased by 50% (from 10 to 15 BPM), the peak PNC decreased by another 49% (9.55 ± 0.21 * 105 # / cm3, 95% CI) and the decay rate increased another 1.72-fold (78.0 ± 9.2 h-1, 95% CI). The minute ventilation was therefore highly correlated, in an inverse manner, with both the peak PNCs and AUC (FIG. 12). Minute ventilation had an opposite effect on the particle decay rates (FIG. 13), which were also highly correlated but in a positive manner (i.e. an increase in the minute ventilation resulted in a corresponding increase in the decay rate).
[0117] The key findings from this example confirm our hypothesis that simpler models for investigating intrapulmonary exposures, such as collecting aerosols in large static chambers, preparing ACM or even exposing cells to diluted aerosol streams, result in dramatically different exposures than are likely to occur within the lung. Such approaches fail to replicate the complex and dynamic exposure patterns that occur in the setting of ongoing breathing. A striking finding from the ventilated artificial lung system was that a 4-puff vaping cycle could result in peak intrapulmonary particle exposure levels averaging 2.61 ± 0.64 x 106 # / cm3. These intense vaping-related exposures, occurring repeatedly and frequently in habitual users, expose the lungAttv. Docket No. 206030-0293-00WG to particle concentrations that are several orders of magnitude higher than those occurring from environmental sources such as air pollution, where PNCs are usually <104 # / cm3[Zhao et al. Indoor Air, 31(3): 818-831, 2021; Rose et al. Atmos Chem Phys, 21(22): 17185-17223, 2021], It is also important to note that vaping topography is highly variable and for individuals who inhale larger puff volumes (ranges 35 to 85 mL), have shorter puffing intervals (range 9 to 55 seconds), and / or inhale greater than 4 puffs in a session (range 10 to 55 puffs), intrapulmonary exposure levels could be substantially higher [Prasad et al. International Journal, 8(12): 366, 2022], A key aspect of this embodiment is that it can be readily adapted to investigate the effects of these different variables on lung exposure. Our findings also demonstrate that ongoing ventilation plays a key role in modulating lung exposures by serially diluting and eliminating retained aerosols with each subsequent breath of fresh air. Even normal quiet breathing can reduce peak PNC and AUC within the lung chamber by approximately 40% and 70%, respectively, when compared to static conditions. Based on these findings, one might expect that individuals sensitive to the irritative effects of e-cig vapor would subconsciously increase respiratory rate and / or tidal volume during their vaping sessions as a mechanism to reduce the magnitude and intensity of exposure. Given the key role of lung volumes on exposure, one would also expect that individuals with smaller lungs or minute ventilations (which vary by age, sex, and ethnicity), and those with altered physiology due to co-existing lung diseases (such as asthma, COPD, restrictive lung diseases), might experience significant differences in aerosol exposure and risk for toxicity. This aspect of inhaled aerosol science warrants additional investigation and is directly empowered by this embodiment of a ventilated artificial lung exposure system.Attv. Docket No. 206030-0293-00WGExample 3: The important role that temperature and humidity play in modulating inhaled particle size, mass and lung deposition patterns.
[0118] Available aerosol research has typically focused on the emission profiles and characteristics of e-cig aerosols when evaluated in experimental chambers or laboratory rooms under room temperature and humidity (25±0.5 °C; 38 ±3% RH) [Das et al. Inhalation Toxicology, 34(3-4): 90-98, 2022; Lee et al. Aerosol Science and Technology, 57(7): 633-644, 2023; Lampos et al. Toxics, 7(3): 45, 2019; Borgini et al. Pulmonology, 2021], However, e-cig aerosols are known to be highly volatile and sensitive to both temperature and RH, which can significantly impact on phase transitioning (gas / solid phases), particle coagulation and hygroscopic changes in aerodynamic particle diameter and mass [Sosnowski et al. Frontiers in Physiology, 9: 853, 2018; Wright et al. Aerosol Science and Technology, 50(12): 1385-1396, 2016; Feng et al. Journal of Aerosol Science, 80: 58-74, 2015; Pichelstorfer et al. Journal of Aerosol Science, 99: 125-132, 2016] and the generation of toxic volatile organic compounds [Huang et al. Scientific Reports, 6(1): 23388, 2016; Zhu et al. Building and Environment, 262: 111845, 2024], As these features directly impact on exposure, it is not clear that prior particle data generated under general room conditions will reflect the behavior of e-cig particles when inhaled into the warm (37°C) and humid (88 ±3% RH) “lung environment”. To directly investigate this concern, we adjusted the humidifier and environmental chamber conditions in our system to compare the fate of e-cig aerosols when inhaled into the lung exposure chamber when it had been set to reflect either “room conditions (25±0.5 °C; 38 ±3% RH)” or “lung conditions (37±0.5 °C; 88 ±3% RH)”. After delivering a standard 4-puff vaping exposure, the ventilator was turned off to create a “snap-shot” of the particle distributions at peak exposure. An APS device was used to characterize larger particle distributions (0.54 to 20 pm) and a SMPSAttv. Docket No. 206030-0293-00WD device was used to measure smaller particle distributions (12 to 455 nm). The warm and humid lung environment, when compared to room conditions, induced a dramatic increase in the size, number and relative mass fraction of micron-sized particles as captured by the APS (FIGs. 14 & 15). However, we noted that limitations from dry sheath airflow associated with the SMPS equipment prevented it from detecting particle growth in the 12 to 455 nm size range (as such, no difference was observed due to this technical issue). Setting the system to reflect the “lung environment” also produced a visible increase in the density of the “vape cloud” within the lung chamber (FIG. 16) due the overall increase in large particles and particle mass.
[0119] As aerodynamic diameter and location (associated with different air flow rates) are key determinants of lung deposition, the dramatic size and mass changes that occur when e-cig particles are inhaled into a warm and humid lung environment (summarized in FIGs. 17 & 18) could significantly impact on deposition pattern in a region-specific manner [Carvalho et al. International Journal of Pharmaceutics, 406(1-2): 1-10, 2011], To investigate this effect, we employed the multiple-path particle dosimetry (MPPD) model (v 3.04) to estimate the deposition fractions and deposition doses throughout the entire human lung, including the upper airway (also referred to as the head airway in the MPPD model), TB airways, and alveoli [Miller et al. Journal of Aerosol Science, 99: 14-26, 2016], The MPPD prediction adopted the stochastic airway geometry and the same breathing pattern as our experimental test (i.e., 10 breaths per min, tidal volume of 480 mL, and oral breath). The total and regional deposition fractions were estimated based on the observed bimodal size distributions of the e-cig aerosols (FIG. 17).According to the MPPD predictions, the hygroscopic growth of e-cig particles in the lung environment is anticipated to lead to significantly higher lung exposure doses and to a change in regional distribution within the airways [Carvalho et al. International Journal of Pharmaceutics,Attv. Docket No. 206030-0293-00WG406(1 -2): 1 -10, 2011], This is important for understanding the pathology of respiratory diseases associated with inhalation exposure [Balashazy et al. Journal of Applied Physiology, 94(5): 1719-1725, 2003; Hofmann. Journal of Aerosol Science, 42(10): 693-724, 2011], Particle growth in the artificial lung was shown to cause over 70% more total deposition fractions compared to the room condition (FIG. 19), but it was not equally distributed. Enhanced deposition was observed predominantly in the upper and TB airways rather than in the alveolar regions, primarily due to the substantial growth of micron-sized particles. Overall, hygroscopic growth resulted in a mass gain of more than 140% for e-cig particles in the warm and humid lung environments. However, elevated deposition fractions do not necessarily reflect the deposition doses of e-cig components, as the increased mass is mainly attributed to water vapor. By applying the same mass fractions distributed for the two aerosol modes as observed at room T / RH in the MPPD model, we estimated that the increase in particle size in the lung environment led to a 19% greater deposition of the underlying e-cig aerosol dose compared to the room condition (FIG. 20). These results emphasize the importance of recreating the warm and humid lung environment in an exposure system and in considering the impact from hygroscopic growth in inhalation exposure assessments, resulting data accurately reflect the potential effect of effects that the higher temperatures and humidity.Example 4: The airway deposition fraction that occurs in 3D printed airways is consistent with MPPD modeling.
[0120] In order for our lung exposure system to accurately reproduce regional lung exposures, it was essential to validate that it performs in a manner consistent with accepted MPPD modeling. As an empiric test of the 3D-printed airways, we delivered different sized particles into theAttv. Docket No. 206030-0293-00WG model and assessed their regional deposition within the combined upper airways and lower conducting airways through G13 (TB tree). For these studies we employed e-cig particles (size distribution as in FIG. 14) as well as standardized Di-Ethyl-Hexyl-Sebacat (DEHS) and sodium chloride (NaCl) particles obtained from commercial vendors. Testing was performed using a resting breathing pattern (10 BPM and 480 mL / breath) or equivalent airflow for the DEHS and NaCl particles, which were delivered by nebulization. The deposition fraction was determined by comparing the particle size distributions and PNC before the inhaled sample entered the airways to that which exited the airways within the exposure chamber. A “U” shaped deposition curve was observed for the size range of 20 to 10000 nm (FIG. 21) with higher deposition fractions for both micron-sized or larger particles and for those with an aerodynamic diameter < 100 nm. For e-cig and NaCl particles, which are primarily nano- and sub-micron particles, the deposition fraction increased as particle diameter decreased. The experiment conducted with DEHS particles provided the deposition fraction for the micron-size range where the deposition fraction increased as particle diameter increased. The obtained size-resolved particle deposition fractions were then compared to results from the multiple-path particle dosimetry (MPPD) predictions for the corresponding upper and TB airways. The MPPD modeling incorporated a similar stochastic airway geometry and the same breathing pattern as used in our experiments. In general, our experimental data exhibited similar trends to those predicted by the MPPD model. The primary differences were observed for the largest particles above 1 micron in diameter, which primarily relate to deposition in the upper airways (mouth, oropharynx and larynx). It is likely that the specific upper airway model employed in our model differs from that predicted by the MPPD model, which incorporates semi-empirical estimations of particle deposition in human lungs across a population - rather than a single representative estimate [Stahlhofen et al. Journal ofAttv. Docket No. 206030-0293-00WGAerosol Medicine, 2(3): 285-308, 1989], However, even these differences were subtle and the overall results clearly validate the utility of our system as an accurate model for airway deposition and the generation of region-specific lung exposures.Example 5: A proof-of-concept test: Employing the artificial ventilated lung exposure system to assess both the intrapulmonary exposure conditions and resulting airway epithelial toxicity at a regional lung level.
[0121] The artificial ventilated lung exposure system described here-in is composed of a unique set of three key components designed to integrate important aspects of lung anatomy, physiology, ventilation, environmental conditions, airway biology and inhalation behavior to produce a more physiologically and biologically relevant inhalation exposure system. As demonstrated in prior examples, each key component introduces elements that significantly alter and improve the assessment of intrapulmonary exposure when compared to existing tools and models. However, when these elements are combined in the manner described, the resulting model is more than a simple sum of its parts. The described components interact in a unique manner that empowers an entirely novel ability to recreate and study several different types of regional lung exposures. Representative embodiments of 3 such regional exposures are depicted in FIGs. 22A, 22B & 22C. Particle deposition in the lung occurs through a combination of direct impaction, sedimentation, Brownian motion and interception [Hinds et al. John Wiley & Sons, 2022], So, in addition to the important role of this model in correcting for intrapulmonary changes in aerodynamic particle size, other features including airway position, cross-sectional area, epithelial surface area, airflow rates, environmental features and the magnitude of turbulence-associated kinetic energy at a specific location also dynamically interact to produceAttv. Docket No. 206030-0293-00WD more realistic particle deposition. During normal breathing, airflow can range from 12-30 L / min at the mouth, producing turbulent flow and high levels of airway impaction. However, airflow dramatically decreases and becomes laminar as particles are inhaled deeper into the lung due to an exponential increase in airway cross-sectional area. Differential airway deposition and phasetransitioning also removes and modifies different subsets of particles and gas exposures along the way, producing an ever-changing exposure based on location and anatomy. There is also a serial dilution of the concentrated vaping puff (20-80 ml) as it is pulled into the mouth and then diluted within a breath of air (200-800 ml) and then within the larger overall lung volume (3-8 L). It is also important to remember that a high percentage of inhaled aerosol is actively exhaled as the lung continues to ventilate and clear itself with ongoing breaths of fresh air. As such, intrapulmonary exposure during vaping is neither uniform nor constant - but rather regional and highly dynamic (FIGs. 22A, 22B & 22C).
[0122] The complexity of modeling lung toxicity from an inhaled aerosol is further complicated by the nature of airway epithelium, which itself changes in a region-specific manner (FIGs. 22A, 22B & 22C) [Davis et al. Mucosal Immunology, 14(5): 978-990, 2021; Silva et al. Eur J Pharm Biopharm, 184: 62-82, 2023], The trachea and bronchi exhibit a ciliated pseudostratified columnar epithelium with goblet cells & mucous secretion (large airways), which transitions into simpler cuboidal epithelium with club cells (small airways) and on to the type I and II alveolar epithelial cells designed to promote gas exchange. As a result, both particle exposures and epithelial type vary dramatically by lung region.
[0123] It is not surprising, considering this heterogeneity in both lung exposure and epithelial structure, that inhalational tobacco-related lung injury (COPD) presents as a complex phenotype. COPD is a highly variable mix of chronic inflammation, chronic bronchitis and emphysemaAttv. Docket No. 206030-0293-00WG[Castaldi et al. Chest, 157(5): 1 147-1157, 2020], The very nature of COPD demonstrates the regional and dynamic nature of aerosol-associated lung disease - i.e, inhaling a complex aerosol can produce multiple different types of lung injury depending on the nature of the regional exposure and the corresponding epithelium. The take-home message is that assessing e-cig toxicity is a complex task and requires tools to assess it at the regional level. Simpler exposure models, such as adding ACM or concentrated puffs of e-cig vapor to cells line in culture, fail to reproduce the dynamic and region-specific exposures that occur within the lungs during vaping and other inhalation exposures. New approaches are needed and this disclosure addresses an important knowledge gap by integrating all of the described features to recreate more realistic lung exposures and toxicity at key regional levels within the lung (FIGs. 22A, 22B & 22C). Airway temperature, humidity, pressure, flow rates, turbulent energy, puff volume, lung volumes, 3D airway modeling, breathing patterns and the nature of the airway epithelium within the region of exposure all matter. When these features are integrated into a single model, they result in a unique system that is capable of recreating regional lung environments that can be studied and assessed in a manner that was not previously possible.
[0124] In the following experimental example, we recreated the bronchiolar epithelial exposure model in which the turbulent airflow that enters the lung at the level of the trachea is converted by the 3D conducting airways into a slow and laminar flow. The exposure that occurs at this level is paired with HBEC cultures growing under ALI conditions, which are specifically supported by the environmental features of this model and represent the associated airway epithelial surface corresponding to this region of the lung.
[0125] In this example, the goal was to assess the bronchiolar exposure conditions and potential biologic impacts when HBECs are repeatedly exposed to realistic puffs of a Juul e-cigAttv. Docket No. 206030-0293-00WG over the course of 2 days. We had previously assessed the response to typical ACM that was prepared from the same Virginia Tobacco Flavor Juul pods and cultured for 24 hrs with cell lines representing airway epithelial cells and tissue macrophages [Ma et al. Environment & Health, 1(5): 315-323, 2023], In those studies, ACM that was variably conditioned with 20 to 120 puffs of e-cig aerosol and these ranges produced dose-dependent effects on cell viability (inducing cell death), oxidative stress and the induction of pro-inflammatory cytokines and chemokines. Similar findings were observed when concentrated ACM was administered directly to the airways of C57BL / 6J mice. As depicted in FIGs. 23A-23E, our standard HBEC cultures were grown under ALI conditions in 12-well Transwell™ insert plates and prior to use it was confirmed by microscopy and histology that they displayed a typical ciliated pseudostratified columnar epithelium with interspersed goblet cells secreting mucus and a layer of basal cells. At the start of the experiment, the artificial ventilated lung exposure system was sterilized and the lung exposure chamber placed into a sterile cell culture incubator rather than a simple environmental chamber. The lung exposure chamber was loaded with the HBEC cultures once the system was equilibrated to reflect the lung environment (37 ±0.5 oC; 88 ±3.0 %RH; 21% O2, 5% CO2, remainder nitrogen). The lung chamber was ventilated throughout the exposures using settings consistent with breathing at rest (480 ml breath; 10 BPM) and then exposed to either the ventilator air alone (air); ventilation with aerosolized puffs of PG / VG alone at a 30 / 70 ratio (PG / VG), which is used as the primary liquid diluent in the Juul pod; ventilation in combination with aerosolized puffs of PG / VG to which 5% nicotine benzoate salt had been added (PG / V G+Nic), which matches the nicotine formulation and concentration in the Juul pod; or to aerosolized puffs generated from the whole commercial Juul pod which contains proprietary flavorings and additives in addition the the PG / VG and nicotine. Each vaping exposure sessionAttv. Docket No. 206030-0293-00WG consisted of 4 puffs that were delivered at 1 min intervals and these 4-puff vaping sessions were repeated every 30 minutes over the course of 6.5 hrs daily (13 sessions, 52 puffs). At the end of the day, cell culture plates were returned to a standard sterile culture incubator and the vaping exposures were then repeated the next day. In total, over the course of two days, cell cultures were exposure to 104 vaping puffs under conditions that model bronchi olar airway exposure as summarized in FIG. 23 A. Monitoring of exposure conditions in the lung chamber included sampling for particle size distributions by SMPS and APS (FIG. 23B), for VOC exposures using a real time sensor probe (USB-VOCIOO, Dracal Technologies Inc., Canada), and for nicotine deposition into culture wells that was subsequently assessed by GC-MS (FIG. 23E). Outcome assays with the HBECs included viability (data not shown as no cell death observed), mitochondrial membrane pore polarization (data not shown as results were normal for all conditions), epithelial histology (FIG. 23D), and the release of Fractalkine (chemokine CX3CL1) by ELISA assay (FIG. 23F). Fracktalkine is a chemokine reported to play a pathogenic role in COPD [Sayed et al. Am J Physiol Lung Cell Mol Physiol, 321(6): LI 134-L1146, 2021; Martin et al. Am J Physiol Lung Cell Mol Physiol, 311(1): L135-L144, 2016], Three to 9 replicates were studied per experiment, with 3 replicate experiments.
[0126] The e-cig aerosol exposure in the bronchi olar airways were similar for all three e- liquid formulations, but not identical, with a trimodal size distribution in the ranges of 20-100 nm, 200-600 nm, and 1-6 microns (FIG. 23B). Vaping exposures from the PG / VG diluent alone resulted in the lowest exposures for the two smaller modes while the intact Juul pod produced the highest exposures for the 20-100 nm particles. Both PG / VG+Nic and the marketed JUUL Virginia Tobacco pods produce the highest exposures for the range of 200-600 nm particles. Large micron-sized particles were nearly identical for all three formulations. Consequently, theAttv. Docket No. 206030-0293-00WGJUUL Virginia Tobacco pods, which contained a complete set of e-liquid constituents, resulted in the greatest number of particles, but the least aerosol mass compared to e-liquids with partial constituents (data not shown). PG / VG alone produced limited exposure to VOCs, while both the PG / VG+Nic and whole Juul formulations resulted in extreme VOC exposures in the range of 2- 2.5 parts per million (2,000-2,500 parts per billion), which would be considered a toxic exposure level. Nicotine exposure levels were lower with the whole Juul formulation than with PG / VG+Nic, consistent with the finding that the whole Juul formulation resulted in the lowest mass exposures.
[0127] Despite prior findings that ACM conditioned with as little as 20 puffs of Juul e-cig vapor was sufficient to induce cytotoxic and inflammatory effects in vitro and in an animal model in vivo, neither cell viability or epithelial histology appeared to be impacted by bronchial exposure to 2 days of repeated vaping. When directly compared, fresh ACM contained 30 to 40- fold higher concentrations of nicotine than could be recovered from culture wells exposed under bronchiolar conditions. Similarly, while exposure to ACM dramatically increased the production of inflammatory cytokines and chemokines, the bronchiolar exposures in our artificial ventilated lung exposure system resulted in significant decreases in the production of Fractalkine - as is the case when samples are collected from the lungs of smokers with COPD [Sayed et al. Am J Physiol Lung Cell Mol Physiol, 321(6): LI 134-L1146, 2021; Martin et al. Am J Physiol Lung Cell Mol Physiol, 311(1): L135-L144, 2016], These unique results from modeled intrapulmonary exposures are consistent with our hypothesis that this system is unique and may provide novel insight into regional lung exposures and toxicity that is not available through other techniques.
[0128] In summary, the creation, testing and validation of a novel artificial lung exposure system is disclosed that replicates human intrapulmonary inhalation exposures. It allows forAttv. Docket No. 206030-0293-00WG monitoring and toxicity to be investigated in novel ways and at regional levels that cannot be evaluated by other approaches. This system has the potential to replace animal and human exposure studies, to facilitate analyses and testing that cannot be carried out with other available models, and can be widely adapted as a tool for assessing aerosol exposures and toxicology relevant to smoking, pollution, exhaust fumes, fire / smoke particulates, environmental gases, asthma, chronic obstructive lung disease, pneumoconiosis, medication delivery and other exposure-related conditions.
[0129] The following publications are herein incorporated by reference in their entireties:
[0130] Keswani, A., H. Akselrod, and S.C. Anenberg, Health and clinical impacts of air pollution and linkages with climate change. NEJM Evidence, 2022. 1(7): p. EVIDra2200068.
[0131] Wang, C.C., et al., Airborne transmission of respiratory viruses. Science, 2021 . 373(6558): p. eabd9149.
[0132] Dinakar, C. and G.T. O’Connor, The health effects of electronic cigarettes. New England Journal of Medicine, 2016. 375(14): p. 1372-1381.
[0133] Sridharan, S., et al., Microplastics as an emerging source of particulate air pollution: A critical review. Journal of Hazardous Materials, 2021. 418: p. 126245.
[0134] Patel, G., et al., Methods to evaluate the toxicity of engineered nanomaterials for biomedical applications: a review. Environmental Chemistry Letters, 2021. 19(6): p. 4253-4274.
[0135] Li, T., et al., A comprehensive understanding of ambient particulate matter and its components on the adverse health effects based from epidemiological and laboratory evidence. Particle and Fibre Toxicology, 2022. 19(1): p. 67.Attv. Docket No. 206030-0293-00WG
[0136] Organization, W.H. Global Health Estimates: Life expectancy and leading causes of death and disability. 2024 [cited 2024 Nov-7]; Available from: https: / / www.who.int / data / gho / data / themes / mortality-and-global-health-estimates.
[0137] Massaro, D. and G.D. Massaro, Toward Therapeutic Pulmonary Alveolar Regeneration in Humans. Proceedings of the American Thoracic Society, 2006. 3(8): p. 709-712.
[0138] EPA., U.S., Guidelines for exposure assessment, U.S.E.P. Agency, Editor. 1992: Washington, DC.
[0139] Das, D., et al., Assessing variability of aerosols generated from e-Cigarettes. Inhalation Toxicology, 2022. 34(3-4): p. 90-98.
[0140] Lee, J., W.-C. Su, and I. Han, Understanding the influence of atomizing power on electronic cigarette aerosol size and inhalation dose estimation. Aerosol Science and Technology, 2023. 57(7): p. 633-644.
[0141] Lampos, S., et al., Real-Time Assessment of E-Cigarettes and Conventional Cigarettes Emissions: Aerosol Size Distributions, Mass and Number Concentrations. Toxics, 2019. 7(3): p. 45.
[0142] Borgini, A., et al., Particulate matter in aerosols produced by two last generation electronic cigarettes: a comparison in a real -world environment. Pulmonology, 2021.
[0143] ICRP, Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection. Ann ICRP, 1994. 24(1-3): p. 1-482.Attv. Docket No. 206030-0293-00WG
[0144] Yue, Y., et al., Size-resolved endotoxin and oxidative potential of ambient particles in Beijing and Zurich. Environmental Science & Technology, 2018. 52(12): p. 6816-6824.
[0145] Hammer, T., et al., Relationship between aerosols exposure and lung deposition dose. Aerosol and Air Quality Research, 2020. 20(5): p. 1083-1093.
[0146] Madureira, J., et al., Assessment of indoor air exposure at residential homes: Inhalation dose and lung deposition of PM10, PM2.5 and ultrafine particles among newborn children and their mothers. Science of The Total Environment, 2020. 717: p. 137293.
[0147] Mellema, M.S., Ventilator waveforms. Top Companion Anim Med, 2013. 28(3): p. 112-23.
[0148] Pleura, lungs, trachea and bronchi, in Gray's Anatomy, S. Standring, Editor. 2020, Elsevier.
[0149] Hall, G.L., et al., Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry. European Respiratory Journal, 2021. 57(3): p. 2000289.
[0150] Sosnowski, T.R. and M. Odziomek, Particle size dynamics: Toward a better understanding of electronic cigarette aerosol interactions with the respiratory system. Frontiers in Physiology, 2018. 9: p. 853.
[0151] Hinds, W.C. and Y. Zhu, Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. 2022, Hoboken, NJ, USA: John Wiley & Sons.Attv. Docket No. 206030-0293-00WD
[0152] Baker, D J., The Structure of the Airways and Lungs, in Artificial Ventilation: A Basic Clinical Guide, D.J. Baker, Editor. 2020, Springer International Publishing: Cham. p. 27- 42.
[0153] Luks, J.B.W.A.M., Structure and Function - how the architecture of the lung subserves its function, in West's Respiratory Physiology. 2020, Wolters Kluwer, p. 1-14.
[0154] Pohunek, P., Development, structure and function of the upper airways. Paediatric Respiratory Reviews, 2004. 5(1): p. 2-8.
[0155] Davies, A. and C Moores, 2 - STRUCTURE OF THE RESPIRATORY SYSTEM, RELATED TO FUNCTION, in The Respiratory System (Second Edition), A. Davies and C. Moores, Editors. 2010, Churchill Livingstone, p. 11-28.
[0156] Miller, F.J., et al., Improvements and additions to the Multiple Path Particle Dosimetry model. Journal of Aerosol Science, 2016. 99: p. 14-26.
[0157] Sosnowski, T.R., Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System. Pharmaceutics, 2024. 16(1).
[0158] Ma, T., et al., Differential Toxicity of Electronic Cigarette Aerosols Generated from Different Generations of Devices In Vitro and In Vivo. Environment & Health, 2023. 1(5): p. 315-323.
[0159] Cao, X., et al., Invited review: human air-liquid-interface organotypic airway tissue models derived from primary tracheobronchial epithelial cells-overview and perspectives. In Vitro Cell Dev Biol Anim, 2021. 57(2): p. 104-132.Attv. Docket No. 206030-0293-00WG
[0160] Son, Y., et al., Investigating e-cigarette particle emissions and human airway depositions under various e-cigarette-use conditions. Chemical Research in Toxicology, 2020. 33(2): p. 343-352.
[0161] Huang, S., et al., Influence of humidity on the initial emittable concentration of formaldehyde and hexaldehyde in building materials: experimental observation and correlation. Scientific Reports, 2016. 6(1): p. 23388.
[0162] Zhu, Y., S. Guo, and W. Liang, A literature review investigating the impact of temperature and humidity on volatile organic compound emissions from building materials. Building and Environment, 2024. 262: p. 111845.
[0163] Siobal, M.S., Monitoring Exhaled Carbon Dioxide. Respiratory Care, 2016. 61(10): p. 1397-1416.
[0164] Grinnan, D.C. and J.D. Truwit, Clinical review: Respiratory mechanics in spontaneous and assisted ventilation. Critical Care, 2005. 9(5): p. 472.
[0165] Movia, D., S. Bruni-Favier, and A. Prina-Mello, In vitro alternatives to acute inhalation toxicity studies in animal models — A perspective. Frontiers in Bioengineering and Biotechnology, 2020. 8: p. 549.
[0166] Yang, S., et al., Environmental toxicology wars: Organ-on-a-chip for assessing the toxicity of environmental pollutants. Environmental Pollution, 2021. 268: p. 115861.
[0167] Banko, A. J., et al., Three-Dimensional Inspiratory Flow in the Upper and Central Human Airways. Experiments in Fluids, 2015. 56: p. 117.Attv. Docket No. 206030-0293-00WG
[0168] Zhang, Z., C Kleinstreuer, and Y. Feng, Vapor Deposition During Cigarette Smoke Inhalation in a Subject- Specific Human Airway Model. Journal of Aerosol Science, 2012. 53: p. 40-60.
[0169] Stanojevic, S., et al., Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. European Respiratory Journal, 2017. 50(3): p. 1700010.
[0170] Kitaoka, H., et al., 4D Model Generator of the Human Lung, “Lung4Cer”, in Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). 2013. p. 453-456.
[0171] Ranpara, A., et al., Effect of Puffing Behavior on Particle Size Distributions and Respiratory Depositions From Pod-Style Electronic Cigarette, or Vaping, Products. Frontiers in Public Health, 2021. 9.
[0172] Talih, S., et al., Characteristics and toxicant emissions of JUUL electronic cigarettes. Tobacco Control, 2019. 28(6): p. 678-680.
[0173] Erythropel, H.C., et al., Flavorant- Solvent Reaction Products and Menthol in JUUL E-Cigarettes and Aerosol. American Journal of Preventive Medicine, 2019. 57(3): p. 425-427.
[0174] Li, L., et al., Effects of Propylene Glycol, Vegetable Glycerin, and Nicotine on Emissions and Dynamics of Electronic Cigarette Aerosols. Aerosol Science and Technology, 2020. 54(11): p. 1270-1281.Attv. Docket No. 206030-0293-00WD
[0175] Prasad, K., A. Gray, and L. Edward, Actual use puffing topography and mouth level exposure to aerosol and nicotine for an evolving series of electronic nicotine delivery systems. International Journal, 2022. 8(12): p. 366.
[0176] Robinson, R.J., et al., Week Long Topography Study of Young Adults Using Electronic Cigarettes in Their Natural Environment. PLOS ONE, 2016. 11(10): p. e0164038.
[0177] Zarei, S., et al., Modeling the airflow in a lung with cystic fibrosis. Journal of NonEquilibrium Thermodynamics, 2013. 38(2): p. 119-140.
[0178] Rabenstein, A., et al. Usage Pattern and Nicotine Delivery during Ad Libitum Consumption of Pod E-Cigarettes and Heated Tobacco Products. Toxics, 2023. 11, DOI: 10.3390 / toxicsl 1050434.
[0179] Vargas-Rivera, M., et al., Effect of flavour manipulation on ENDS (JUUL) users’ experiences, puffing behaviour and nicotine exposure among US college students. Tobacco Control, 2021. 30(4): p. 399.
[0180] Zhao, J., et al., Particle number emission rates of aerosol sources in 40 German households and their contributions to ultrafine and fine particle exposure. Indoor Air, 2021. 31(3): p. 818-831.
[0181] Rose, C., et al., Seasonality of the particle number concentration and size distribution: a global analysis retrieved from the network of Global Atmosphere Watch (GAW) near-surface observatories. Atmos. Chem. Phys., 2021. 21(22): p. 17185-17223.
[0182] Wright, T.P., et al., Thermodynamic and kinetic behavior of glycerol aerosol. Aerosol Science and Technology, 2016. 50(12): p. 1385-1396.Attv. Docket No. 206030-0293-00WD
[0183] Feng, Y., C. Kleinstreuer, and A. Rostami, Evaporation and condensation of multicomponent electronic cigarette droplets and conventional cigarette smoke particles in an idealized G3-G6 triple bifurcating unit. Journal of Aerosol Science, 2015. 80: p. 58-74.
[0184] Pichelstorfer, L., et al., Simulation of aerosol dynamics and deposition of combustible and electronic cigarette aerosols in the human respiratory tract. Journal of Aerosol Science, 2016. 99: p. 125-132.
[0185] Carvalho, T.C., J.I. Peters, and R.O. Williams, Influence of particle size on regional lung deposition - What evidence is there? International Journal of Pharmaceutics, 2011. 406(1- 2): p. 1-10.
[0186] Balashazy, I., W. Hofmann, and T. Heistracher, Local particle deposition patterns may play a key role in the development of lung cancer. Journal of Applied Physiology, 2003. 94(5): p. 1719-1725.
[0187] Hofmann, W., Modelling inhaled particle deposition in the human lung — A review. Journal of Aerosol Science, 2011. 42(10): p. 693-724.
[0188] Stahlhofen, W., G. Rudolf, and A.C. James, Intercomparison of Experimental Regional Aerosol Deposition Data. Journal of Aerosol Medicine, 1989. 2(3): p. 285-308.
[0189] Davis, J.D. and T.P. Wypych, Cellular and functional heterogeneity of the airway epithelium. Mucosal Immunol, 2021. 14(5): p. 978-990.
[0190] Silva, S., et al., Air-liquid interface (ALI) impact on different respiratory cell cultures. Eur J Pharm Biopharm, 2023. 184: p. 62-82.Attv. Docket No. 206030-0293-00WG
[0191] Castaldi, P.J., et al., Machine Learning Characterization of COPD Subtypes: Insights From the COPDGene Study. Chest, 2020. 157(5): p. 1147-1157.
[0192] Sayed, I.M., et al., Inflammatory phenotype modulation in the respiratory tract and systemic circulation of e-cigarette users: a pilot study. Am J Physiol Lung Cell Mol Physiol, 2021. 321(6): p. LI 134-11146.
[0193] Martin, E.M., et al., E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. Am J Physiol Lung Cell Mol Physiol, 2016. 311(1): p. L135-44.
[0194] Chen, Haoxuan, et al. "A Ventilated Three-Dimensional Artificial Lung System for Human Inhalation Exposure Studies." Environmental Science & Technology 58.52 (2024): 22919-22929.
[0195] Li, Liqiao, et al. "Ventilation and features of the lung environment dynamically alter modeled intrapulmonary aerosol exposure from inhaled electronic cigarettes." Scientific Reports 14.1 (2024): 31683.
[0196] The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this disclosure has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this disclosure may be devised by others skilled in the art without departing from the true spirit and scope of the disclosure. The appended claims are intended to be construed to include all such embodiments and equivalent variations.
Claims
Attv. Docket No. 206030-0293-00WGCLAIMS1. An artificial ventilated lung exposure system, comprising: a temperature-controlled incubator including at least one port; an artificial lung chamber positioned within the incubator, in fluid connection with the at least one port, and comprising a plurality of walls; an airway model at least partially positioned within the artificial lung chamber; at least one test lung balloon in fluid connection with the artificial lung chamber; and at least one sensor within the artificial lung chamber; wherein the artificial ventilated lung exposure system is designed to both simulate and assess modeled human lung inhalation exposures by integrating:A) an airtight lung exposure chamber that reproduces human lung anatomy in terms of lung shape, specified lung volumes, and the presence of modeled airway structures through which air flows in and out of the exposure chamber;B) a simulation of the dynamic processes involved in breathing including a) an inhalation phase that delivers a set volume to the lung exposure chamber; b) an exhalation phase that eliminates a set volume from the lung exposure chamber; and c) a control mechanism for adjusting the delivered volumes, respiratory rates and patterns;C) mechanisms for environmental control including control of temperature, relative humidity, intra-chamber gas composition and volume-associated pressure changes (compliance) within the lung exposure chamber.Attv. Docket No. 206030-0293-00WG2. The system of claim 1, further comprising a series of integrated access ports for monitoring internal chamber conditions including temperature, relative humidity, pressure, gas composition, concentration of total or specific volatile organic compounds, particle number concentrations, particle size distributions, particle mass distributions, and particle composition.
3. The system of claim 1, wherein the artificial ventilated lung exposure system is configured to support, in a sterile environment, the culture and exposure of cells and tissues to the environment within the lung exposure chamber during the inhalation of a test sample and during ongoing breathing.
4. The system of claim 1, wherein cells and tissues are placed into the lung exposure chamber for exposure testing.
5. The system of claim 1, wherein cells and tissues are cultured directly on an internal surface of modeled airway structures and lung surfaces for exposure testing.
6. The system of claim 1, wherein the lung exposure chamber exhibits a modified conical shape that represents the anatomical proportions of a single human lung, either left or right, or a pair of individual lungs including both a right and a left lung.
7. The system of claim 1, wherein the right and left lung compartments are openly connected within the chamber or divided, in part or in whole, into two or more individual compartments corresponding to anatomical subdivisions of the whole lung.
8. The system of claim 1, wherein the specified lung volumes represent any of the following standard subdivisions of lung volume, alone or in combination, including the total lung capacity,Attv. Docket No. 206030-0293-00WG inspiratory capacity, functional residual capacity, vital capacity, expiratory reserve volume, residual volume, inspiratory reserve volume, and tidal volume or a specified fraction (percentage) of stated volumes.
9. The system of claim 1, wherein a model of the airway structures through which air flows includes a physical 3 -dimensional (3D) representation of the upper airways, in whole or in part, defined as including models for the nasal passages and nasopharynx, mouth and oropharynx and laryngeal airway.
10. The system of claim 1, wherein a model of the airway structures through which air flows includes a physical 3D representation of the lower conducting airways, in whole or in part, defined as including models for branching airway structures from the trachea (branch generation 0; GO) to the terminal bronchiole (branch generation 16; G16).
11. The system of claim 1, wherein a model of the airway structures through which air flows includes a physical 3D representation of the gas-exchange regions of the lung, in whole or in part, defined as including models representing the cross-sectional areas and / or surface area of the respiratory bronchioles (branch generations 17-19; G17-G19), alveolar ducts (branch generations 20-22; G20-G22), and alveolar sacs (branch generation 23; G23).
12. The system of claim 1, wherein the model of the airway structures includes any individual element or a combination of elements selected from the nasal passages and nasopharynx, mouth and oropharynx, laryngeal airway, branching airway structures from the trachea (branch generation 0; GO) to the terminal bronchiole (branch generation 16; G16), and / or the gas-exchange regions of the lung, in whole or in part, defined as including models representing the cross-sectional areas and / or surface area of the respiratory bronchioles (branchAttv. Docket No. 206030-0293-00WG generations 17-19; G17-G19), alveolar ducts (branch generations 20-22; G20-G22), and alveolar sacs (branch generation 23; G23).
13. The system of claim 1, wherein the specific elements included in the model of the airway structures are set to match the flow characteristics appropriate for the type of airway cells and airway epithelium that are present in the corresponding region of the lung; thereby producing a region-specific exposure condition such as the central airway airflow matched to human bronchial cells and human bronchial epithelium, the conducting airway region matched to small airway cells and small airway epithelium, and the gas-exchange regions of the lung matched to alveolar cells and alveolar epithelium.
14. The system of claim 1, wherein the relative size and 3D-structure of the modeled airway parts are derived from anatomic measurements, castings prepared from human lungs, data generated from computerized tomography imaging of the airways, theoretical modeling and in silico simulations.
15. The system of claim 1, wherein features of the lung exposure chamber are generated through molding, extrusion, 3D-printing, fabrication, mechanical assembly, welding, and fusion.
16. The system of claim 1, wherein the mechanism to simulate the inhalation and exhalation of a breath includes the attachment of a ventilator, lung volume simulator, respiratory bellows, two-way syringe system, aerosol generating device, or a pressurized gas flow device.
17. The system of claim 1, wherein the breath is delivered using a positive pressure to force a breath into the lung exposure chamber.
18. The system of claim 1, wherein the breath is delivered through the generation of aAttv. Docket No. 206030-0293-00WG negative pressure within the lung exposure chamber that draws in the breath from an external air source.
19. The system of claim 1, wherein In some examples, the delivery of the inspiratory breath includes a mechanism for introducing a test aerosol into the inhaled breath.
20. The system of claim 1, wherein the mechanisms to simulate the exhalation of a breath occur through an active process such that when triggered it actively removes a breath.
21. The system of claim 1, wherein the mechanisms to simulate the exhalation of a breath occur through a passive process mediated by the elastic rebound properties, also termed compliance, of the artificial ventilated exposure chamber system.
22. The system of claim 1, wherein the elastic rebound properties of the artificial ventilated exposure chamber are determined by one or more of the use of attached lung test balloons, respiratory bellows, a two-way syringe system, a lung simulator device, elastic material used in production of the airway structures, and elastic materials used in production of the exposure chamber walls.
23. The system of claim 1, wherein the adjustable controls for the respiratory rate and tidal volume are provided as a component of the device(s) that provides the inhalation and exhalation.
24. The system of claim 1, wherein the adjustable controls for the respiratory rate and tidal volume are provided or as part of a central control software that integrates different operational components into a central computer-controlled process.
25. The system of claim 1, wherein the temperature within the lung exposure chamber is independently controlled, with respect to the existing room environment, through use of at leastAttv. Docket No. 206030-0293-00WG two different heat sources.
26. The system of claim 25, wherein one heat source is a heated ventilator circuit that heats the air, gas and aerosol sources as they travel through tubing that delivers them into the lung exposure chamber with each breath.
27. The system of claim 25, wherein one heat source independently heats the lung exposure chamber from the outside to assure uniform temperature control throughout the model and to specifically prevent condensation on either the interior or exterior surfaces of the chamber and modeled airway structures.
28. The system of claim 1, wherein humidity is controlled, in whole or in part, through use of a heated ventilator humidifier circuit.
29. The system of claim 1, wherein humidity is controlled, in whole or in part, through use of a heated water reservoir contained within the lung exposure chamber.
30. The system of claim 1, wherein the chamber gas composition within the lung exposure chamber is controlled by delivering air and gases into the chamber from at least one source including room air, a sample chamber that contains a controlled gas composition, and the use of different compressed gas sources in combination with pressure and gas-mixture regulating valves as needed to obtain the desired gas composition.
31. The system of claim 30, wherein the gas composition is 21% Oxygen, 5% Carbon Dioxide and remainder Nitrogen.
32. The system of claim 1, wherein a central integrated software program integrates and controls the various adjustable features of the artificial ventilated lung exposure system.
